Slit1 and MEGF4 isoforms and their use

ABSTRACT

The invention relates to new Slit1 or MEGF4 sequences and their uses in connection with the diagnosis and/or treatment of cancer or the screening for substances binding to Slit1 and/or MEGF4, in particular prospective inhibitors.

FIELD OF THE INVENTION

[0001] The invention relates to new Slit1 and MEGF4 isoforms, to the use of sequences derived from Slit1 and MEGF4 for screening for substances binding thereto, and to the use of substances binding to Slit1 and/or MEGF4 for diagnosing and/or treating cancer diseases.

BACKGROUND OF THE INVENTION AND PRIOR ART

[0002] Secreted Slit1 and MEGF4 proteins being different transcriptional isoforms have been well researched in neurological correlations. In the embryogenesis of drosophila, the slit gene plays an essential role for the structure of the central nervous system.

[0003] From the document Itoh et al., Molec. Brain Res., 62:175-186 (1998), it is known in the art that three human homologs, Slit1, Slit2 and Slit3, to the slit gene of the drosophila exist. Each of these genes codes a protein comprising conserved protein-protein interactions, for instance leucine-rich repeats (LRR1-LRR4) and EGF-like motives (EGF1-EGF9), similar to the drosophila gene. Human Slit1 is known under XM_(—)005958 or NM_(—)003061. Analyses have shown that a larger 8.4 kb and a smaller 5.9 kb transcript of Slit1 is expressed substantially in the brain. Slit2 and Slit3 are expressed substantially in the spinal cord and the thyroid gland.

[0004] According to the document M. Nakajama et al., Genomics, 51:27-34 (1998), the Slit1 gene (there called MEGF4) is on chromosome 10q23.3-q24.

[0005] Different documents deal with the role of Slit or MEGF in the generation of and function in neural tissues of mammals. As an example only, reference is made to W. Wu et al., Nature 400:331-336 (1999), W. Yuan et al., Developmental Biology 212:290-306 (1999), T. Kidd et al., Cell 96: 785-794 (1999), Y. Liang et al., JBC 274:17885-17892 (1999), and E. Stein et al., Science, 291: (2001).

[0006] In the document JP11164690, the diagnosis and the treatment of cancer diseases is described in the most general form, without any detailed specification of the kind of the cancer disease, by means of a biologically active form of the Slit1 protein.

[0007] Cancer, in particular prostate or breast cancer, but also other cancer diseases, is a disease occurring with increasing age at a considerable incidence. Up to now, cancer is diagnosed substantially pathologically and is treated in most cases by removal of the respective organ. The removal of an organ has various disadvantageous effects on a patient. An improved diagnosis and treatment of cancer, in particular without the necessity of removing an organ or of a part thereof, is therefore highly desirable.

TECHNICAL OBJECT OF THE INVENTION

[0008] The invention is based on the technical object to specify pharmaceutical compositions for diagnosing and/or treating cancer diseases.

BASICS OF THE INVENTION AND PREFERRED EMBODIMENTS

[0009] For achieving the technical object, the invention teaches firstly a nucleic acid coding for a Slit1 or MEGF4 isoform comprising a nucleic acid sequence according to Seq.-ID 2, 3, 4, 5, 25, or 26 and a Slit1 or MEGF4 peptide or protein comprising an amino acid sequence according to Seq.-ID 7, 8, 9, 10, 11, 12, 13, 14, 27, or 28. The nucleic acid or the peptide or protein may in particular be composed of these sequences. The said sequences are new isoforms of the human Slit1 or MEGF4. Nucleic acids or proteins or peptides according to the invention can be prepared by the usual molecular biological methods.

[0010] The invention further relates to various uses of the new nucleic acids or peptides or proteins, and to (identical) uses of already known Slit1 or MEGF4 nucleic acids. These are:

[0011] i) the use of a nucleic acid coding for Slit1 or MEGF4 and/or of a Slit1 or MEGF4 peptide or protein for the detection of cancer or for the detection of a risk of a cancer disease, a tissue sample (of the respective organ, an arbitrary tissue sample for the detection of metastases from the below cancer types) being examined for the transcription or over-transcription of Slit1 or MEGF4 RNA or for the transcription or over-expression of a Slit1 or MEGF4 protein, preferably a nucleic acid coding for Slit1 or MEGF4 or a detector substance binding to a Slit1 or MEGF4 protein or peptide being used, said detector substance preferably comprising a reporter group, the binding of the said nucleic acid and/or the said protein or peptide to the detector substance being detected in a semi-quantitative or quantitative manner, and the cancer disease preferably being selected from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”,

[0012] ii) the use of a Slit1 or MEGF4 RNA or of a Slit1 or MEGF4 protein or peptide for screening for substances binding thereto, in particular prospective drugs for inhibiting the said RNA or the said protein or peptide or prospective detector substance, a prospective substance or a mixture of such prospective substances being contacted with the said RNA or the said protein or peptide, binding events being determined by means of a binding assay, and a binding prospective substance being selected, if applicable after deconvolution,

[0013] iii) the use of a substance inhibiting Slit1 or MEGF4 for preparing a pharmaceutical composition for the treatment of cancer and/or a metastases generation from a primary tumor, the cancer disease or the primary tumor, respectively, being selected from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”.

[0014] A substance used for the invention may be selected from the group comprising:

[0015] a) antisense oligonucleotides, siRNA, and ribozymes against a nucleic acid according to claim 1,

[0016] b) an organic molecule binding to a peptide or protein according to claim 2, in particular identified according to claim 5, and having a molecular weight below 5,000, preferably below 1,000, most preferably below 300,

[0017] c) an aptamer against a protein or peptide according to claim 2, in particular identified according to claim 5,

[0018] d) a (monoclonal) antibody, in particular human or humanized antibody against a protein or peptide according to claim 2,

[0019] e) an anti-idiotypic non-human (monoclonal) antibody, generated by means of an antibody of the sub-group d), and

[0020] f) the above substances derivatized with a reporter group, a cell toxin, an immuno-stimulating component and/or a radio isotope.

[0021] In the case a), a hammerhead ribozyme may for instance be used. The ribozyme interface is selected such that by the activity of the ribozyme the expression of the protein is either suppressed, or an inactive form or an inactive fragment of the protein is expressed. Both may for instance be detected by that in a cell system, wherein a protein according to the invention is expressed on a defined level, this cell system is contacted with one or more ribozymes modeled for defined interfaces, and the expression level or the biological activity of the expressed protein is determined. This is then compared to a negative sample or to the results without contacting, and those ribozymes are selected that lead to a lower expression or activity. In a corresponding manner, siRNA or the antisense nucleic acids may be treated. In the case a), all sequences are usable.

[0022] In the case b), chemical substance libraries may be employed in order to screen for binding substances. A validation of binding substances for therapeutic purposes may be performed by determination of the biological activity of the protein in a cell system with and without contacting and comparison of the obtained results. For therapeutic purposes, then such substances are selected which lead to a reduced biological activity. It is also possible that in a screening method according to the invention, the biological activity is determined at the position of binding; then a validation in the above sense has been performed together with the screening. Biological activity may for instance be determined by that natural association partners of the protein are determined and the occurrence and form thereof (e.g. monomer/dimer/heterodimer) are examined. Substances generated further downstream in a metabolism cascade may also be used as an indicator; these substances may for instance be identified by that before cell components are analyzed for the cell expressing the protein, and a comparison is made with identical cells, wherein the expression is however gene-technologically deleted. Mimicry compounds being able to specifically bind the functionally active center of the enzyme domains containing proteins and to inhibit them in their biological activity may also be derived. If a mimicry compound is able to specifically bind the peptides, without inhibiting it in its biological function, it may nevertheless contribute to the achievement of the technical and medical object. As a good binder, it may be derivatized with a cell toxin, in order to thus kill the target cells in a targeting approach. Such a cell toxin my be a classic chemotherapeutical, but also a radio isotope. Further, such peptide specific mimicry compounds, derivatized with a reporter group, may be used as a compound in tumor diagnostics.

[0023] Suitable aptamers c) may easily be identified for instance by the well known SELEX method, the protein according to the invention being used as a target. All sequences may be employed.

[0024] Antibodies d), in particular monoclonal antibodies, may be obtained in a usual way by immunization of a non-human mammal with a protein according to the invention, a nucleic acid according to the invention (e.g. cDNA), a cell (cancer cell or for instance cell transfected with a nucleic acid according to the invention, such as COS or NIH3T3) constitutively expressing a protein according to the invention, or by means of recombinantly prepared protein or peptide, for instance expressed in E. coli or eukaryote cells (e.g. insect cells). Monoclonal antibodies are obtainable by usual selection and establishment of hybridoma cells. The phage display technique may also be used for the generation of the antibodies. For the case d), the following is to be noted. Starting from a sequence according to the invention, an antibody may be derived in a human and/or humanized form, said antibody being able to specifically bind to the functionally active center of the proteins and to inhibit their biological activity. Further, such a peptide specific antibody, derivatized with a reporter group, may be used as a compound in the tumor diagnostics.

[0025] In the case of the anti-idiotypic antibodies e), these are obtainable by that by means of an antibody according to the invention that needs not necessarily influence the biological activity of the protein according to the invention, a second anti-idiotypic (monoclonal) antibody is generated in a non-human mammal. This anti-idiotypic antibody feigns then when applied in human cells a picture of the target molecule to the human immune system and is detected as a non-self epitope due to its non-humanized from. Man consequently naturally generates antibodies against the anti-idiotypic antibody and thus also against the protein or against cells expressing the protein. This variant of the invention is exclusively usable for therapeutic purposes. Starting from sequences according to the invention, monoclonal mouse/rat antibodies can be derived. The monoclonal antibodies Ab1 need not necessarily be able to specifically bind the functionally active center of the proteins and inhibit their biological activity. The monoclonal antibodies Ab1 are used in a second step in order to generate second anti-idiotypic mouse monoclonal antibodies aAB1. The monoclonal aAB1's represent the link for the solution of the technical and medical object by “feigning” an image of the antigen to the human immune system and detecting it by its non-humanized form as a non-self epitope. The human body inevitably generates own antibodies against aAB1 and thus against the tumor cells expressing the target protein. Whereas the aAB1 antibodies are exclusively suitable for the treatment of the tumor disease, the Ab1 antibodies are exclusively used for the diagnostic solution of the problem.

[0026] In the case f), starting from nucleic acids according to the invention and/or the amino acid sequences, antibodies and/or mimicry compounds can be isolated with a high specific binding activity. Such substances are then in a second step derivatized with cell toxins and used for targeting the tumor cells.

[0027] The invention further relates to a method for diagnosing a cancer disease, wherein a detector substance according to the invention in the embodiment with a reporter group is applied into tissue to be examined (being left in the organism or taken therefrom), the tissue to be examined being then subjected to a detection method step being sensitive for the reporter group, and wherein in the case of the detection of a defined minimum value of the reporter group in the tissue the tissue is qualified as containing tumor cells, and to a method for treating a cancer disease, preferably a cancer disease selected from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”, wherein a pharmaceutical composition according to the invention is administered in a physiologically effective dose and usual galenic preparation to a patient.

[0028] The invention is based on the finding that Slit1 or MEGF4 is differentially expressed in tumor tissue, in particular prostate or breast tumor tissue, i.e. in these tissues the expression is higher compared to normal cells of the same tissue. This allows on the one hand to use Slit1 or MEGF4 as markers for the identification of tumor cells in suspicious tissue, for instance in the prostate or the breast. On the other hand, the inhibition of Slit1 or MEGF4, in particular also with local application, offers the possibility to influence the tumor-specific Slit1 or MEGF4 associations by other processes in the tumor cells and thus at last to disturb the tumor-specifically modified metabolism and contribute to the death or at least to a growth inhibition of the tumor cells or inhibit the metastasization. Corresponding considerations apply to the case of the metastasization, since Slit1 or MEGF4 is able to inhibit the SDF-1alpha induced, CXCR4 mediated chemotaxis.

[0029] For the purpose of the invention, it may be recommendable, prior to a treatment with a pharmaceutical composition according to the invention, to take a sample from a tissue identified by other methods as a tumor tissue, and to examine the tissue sample for expression or over-expression of Slit1 or MEGF4. Alternatively, a test for Slit1 or MEGF4 dependence can be performed with a detector substance according to the invention for in vivo diagnosis. If an expression or over-expression of Slit1 or MEGF4 compared to normal tissue of the same type is detected, the application of the pharmaceutical composition according to the invention is indicated.

[0030] If the tumor is a type, wherein tumor cells express Slit1 or MEGF4, not however or only weakly normal cells of the same tissue type, it is particularly preferred that the substance binding to Slit1 or MEGF4 in addition carries a cytotoxic and/or immunostimulating component. This at last leads to that virtually exclusively tumor cells are killed, by cytotoxicity or by an attack by the stimulated immune system, whereas normal cells in the tissue are virtually completely preserved. In this embodiment, the binding substance needs not act inhibitingly on Slit1 or MEGF4, since this binding substance needs only function as a marker carrying the components to target tumor cells. In the case of using a cytotoxic and/or immunostimulating component, it may be particularly recommendable that the pharmaceutical composition is suited for a local application in a tissue containing tumor cells, for instance by injection.

[0031] By means of substances according to the invention, in particular peptides and proteins, it is at last possible to perform an immunotherapy by way of vaccination with epitopes of the Slit1.

[0032] Definitions.

[0033] In this specification, the term Slit1 or

[0034] MEGF4 is used for all human isoforms, known or new, on nucleic acid or amino acid basis. Also included in this term are the short sequences disclosed in this specification, said short sequences originating from the isoforms, for instance immunization sequences. Further included are homologs, the homology being at least 80%, preferably more than 90%, most preferably more than 95%. In the case of the nucleic acid sequences, complementary or allelic variants are also included. Further such sequences are included, which represent only partial sequences of the explicitly disclosed sequences, for instance an exon or several exons, or complementary sequences hereto, such that these partial sequences in the case of the nucleic acids comprise a length sufficient for a hybridization with a nucleic acid according to the invention, at least 50 bases, and in the case of the proteins or peptides bind with at least identical affinity to a protein or peptide-specific target molecule. Further, all nucleic acids hybridizing with nucleic acids according to the invention are included, which hybridize under stringent conditions (e.g. 5° C. to 25° C. below the melting temperature; see also J. M. Sambrock et al., A laboratory manual, Cold Spring Harbor Laboratory Press (1989) and E. M. Southern, J Mol Biol, 98:503ff (1975)). It is understood that the invention also covers expression cassettes, i.e. one or more of the nucleic acid sequences according to the invention having at least one control or regulatory sequence. Such an expression cassette may also comprise a sequence for a known protein, in the course of the translation a fusion protein from a known protein and a protein or peptide according to the invention being generated. Further, antisense sequences to the above nucleic acid sequences are also included. Finally, RNA and DNA correlating therewith and vice versa are included, same as genomic DNA as well as correlated cDNA and vice versa.

[0035] For the uses according to the invention, the terms Slit1/MEGF4 nucleic acids or proteins or peptides also include, in addition to the full lengths of the disclosed sequences (see also previous paragraph), partial sequences hereof, with a minimum length of 12 nucleotides, preferably 30 to 90 nucleotides in the case of the nucleic acids, and a minimum length of 4 amino acids, preferably 10 to 30 amino acids in case of the peptides or proteins.

[0036] The terms of the detection and/or treatment of cancer, for instance prostate cancer and/or breast cancer, also include the detection and/or treatment of metastases from primary tumors in other tissues. The term of the treatment also includes the prophylaxis.

[0037] An inhibitor is a compound or substance that either inhibits the generation of Slit1 or MEGF4 or reduces the activity of generated Slit1 or MEGF4, compared to the Slit1 or MEGF4 activity in absence of the inhibitor. In so far an inhibitor may on the one hand be a substance influencing in an inhibiting manner the generation cascade of Slit1 or MEGF4. On the other hand an inhibitor may be a substance that enters in a binding relation with the generated Slit1 or MEGF4, in such a way that further physiological interactions with endogenic substances are at least reduced.

[0038] Mimicry compounds are compounds reproducing the variable section, in particular the binding section of an antibody, and bind at the same position of a target molecule as the respective antibody.

[0039] The term of the antibodies includes polyclonal antibodies, monoclonal antibodies, non-human, human and humanized antibodies, anti-idiotypic antibodies and phage display antibodies, but also chimeric antibodies and specific fragments of the light and/or heavy chain of the variable section of respective antibodies of the above type. The preparation or recovery of such antibodies with given immunogens is well known to the average man skilled in the art and needs not be explained in more detail here. Further the term of the antibodies includes bispecific antibodies. Bispecific antibodies combine a defined immune cell activity with a specific tumor cell detection, thus tumor cells being killed. A bispecific antibody binds on the one hand to a trigger molecule of the immune effector cell (e.g. CD3, CD16, CD64) and on the other hand to antigens of the tumor target cell.

[0040] The galenic preparation of a pharmaceutical composition according to the invention may be performed in a manner suitable for this technology. As counter-ions for ionic compounds may for instance be used Na⁺, K⁺, Li⁺ or cyclohexylammonium. Suitable solid or liquid galenic preparation types are for instance granulates, powders, dragees, tablets, (micro-) capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions (IV, IP, IM) and preparations with protractable drug release, for the production of which usual auxiliary means are used, such as carrier substances, blasting, binding, coating, swelling, sliding or lubricating agents, flavors, sweeteners and emulgators. As auxiliary substances are named here magnesium carbonate, titanium dioxide, lactose, mannite and other sugars, talcum, milk protein, gelatin, cellulose and its derivatives, animal and vegetable oils such as cod-liver oil, sunflower, peanut or sesame oil, polyethylene glycols and solvents, such as sterile water and mono or poly-valent alcohols, for instance glycerin. A pharmaceutical composition according to the invention can be prepared by that at least one Slit1/MEGF4 inhibitor is mixed in a defined dose with a pharmaceutically suitable and physiologically carrier and if applicable further suitable drug, additional or auxiliary substances having a defined inhibitor dose and provided in the desired administration manner.

[0041] Tumor cells express Slit1 or MEGF4 in a differential manner, whereas normal cells of the same tissue do not express this. Tumor cells over-express Slit1 or MEGF4 in a specific or differential manner, when Slit1 or MEGF4 is, compared to normal cells of the same tissue, expressed higher, for instance at least in a double amount.

[0042] Cytotoxic components or groups are compounds directly or indirectly initiating apoptosis or leading to necrosis or at least acting in a growth inhibiting manner. Such groups or compositions may be, in addition to radioisotopes (for instance 188Re, 213Bi, 99 mTc, 90Y, 131J, 177Lu), in particular cytostatic substances used in tumor therapy. Examples for these are alkylating agents (for instance mechlorethamine, ifosfamide, chlorambucil, cyclophosphamide, melphalan, alkyl sulfonates, busulfan, nitrosoureas, carmustine, lomustine, semustine, triazine, dacarbazine), antimetabolites (for instance fol acid antagonists, methotrexate, pyrimidine analogs, fluoruracil, fluordesoxyuridin, cytabarine, gemcitabine, purine analogs, mercaptopurine), mitosis inhibitors (for instance vinca alcaloids, vincristine, vinblastine, paclitaxel, docetaxel, proteaxel), epipodophyl lotoxins (for instance etoposide, teniposide), antibiotics (for instance dactinomycin, daunorubicin, idarubicin, anthracyclines, bleomycin, L-asparaginase), platinum complex compositions (for instance cisplatin), hormones and related compositions (for instance suprarenal gland steroids, aminogluthetimide, gestagens, estrogens, androgens, antiestrogens, tamoxifen, steroid analogs, flutamide). When such a composition is bound to a substance binding Slit1 or MEGF4, the coupling takes place such that the affinity to Slit1 or MEGF4 is reduced by not more than 90%, preferably 50%, referred to the substance without cytostatic group, and the cytostatic effect of the group is reduced by not more than 90%, preferably 50%, referred to the composition without substance.

[0043] An immunostimulating component is in most cases a protein or an effective component thereof stimulating cells of the immune system. Examples are cytokines such as M-CSF, GM-CSF, GCSF, interferons such as IFN-alpha, beta, gamma, interleukins such as IL-1 to -16 (except -8), human LIF, chemokines such as rantes, MCAF, MIP-1-alpha, -beta, NAP-1 and IL-8.

[0044] A reporter group is an atom, a molecule or a compound permitting in conjunction with a suitably adapted assay the detection of the reporter group and thus of the compound or substance connected with the reporter group. Examples for reporter groups and detection methods associated herewith are: 32P labeling and intensity measurement by using a phosphoimager. Many other examples, for instance detection of fluorescence, are well known to the average man skilled in the art and need not be described in detail.

[0045] A substance binding to Slit1 or MEGF4 may be a substance binding a Slit1 or MEGF4 protein or a Slit1 or MEGF4 RNA.

[0046] Any terms in the above definition extended in their meaning relative to the precise meaning of the word shall also include the respective terms in the precise meaning of the word.

EXAMPLES

[0047] In the following, the invention is described in more detail, based on examples representing preferred embodiments only. There are:

[0048]FIG. 1 a chip analysis for the differential expression of Slit1 or MEGF4 in prostate tumor tissues from 54 patients,

[0049]FIG. 2 a Taqman® analysis for the differential expression of Slit1 or MEGF4 in prostate tumor tissues from 14 patients,

[0050]FIG. 3 Western blots for Slit1 or MEGF4 detected by means of antisera according to the invention,

[0051]FIG. 4 an IHC detection of Slit1 over-expression in prostate tumor cells,

[0052]FIG. 5 a Facs analysis for the localization of the Slit1 or MEGF4 protein,

[0053]FIG. 6 5 different hammerhead ribozymes cutting Slit1 or MEGF4 or tSlit1 (Seq.-ID 5) mRNA,

[0054]FIG. 7 the detection of recombinant human SLIT from stably transfected HEK293 cells with the antibody prt87 B2,

[0055]FIG. 8 the detection of the binding of SLIT1 to heparin agarose,

[0056] FIGS. 9 to 14 the purification of SLIT1,

[0057]FIG. 15 a graphic representation of shortened peptide sequences including domains.

Example 1 Over-Expression in Prostate Tumor

[0058] Paired tumor and normal tissue was taken by laser microdissection from 54 patients. The RNA prepared therefrom was labeled with dioxygenin and hybridized on a DNA chip by means of the Affymetrix technology. The results of the analysis of the chip are shown in FIG. 1 (ordinate: expression ratio tumor/normal tissue; abscissa: 54 patients having prostate tumor). It can be seen that in 26 of 54 patients there is no differential expression, in 2 of 54 there is a down-regulation and in 26 of 54 there is an up-regulation of Slit1/MEGF4 (factor >2).

[0059] This finding was checked by means of the Taqman® analysis. Paired tumor and normal tissue of 14 patients was obtained by laser microdissection. The RNA prepared therefrom was reversely transcribed. The thus obtained cDNA was used as a template in quantitative PCR. The results are shown in FIG. 2 (ordinate same as in FIG. 1; abscissa: 14 patients having prostate tumor). No differential expression of Slit1/MEGF4 was detected in 6 of 14 patients, and an up-regulation of the transcription was detected in 8 of 14.

[0060] Thus it is proven that the expression of Slit1/MEGF4 in at least 50% of the prostate tumors are up-regulated, so that Slit1/MEGF4 is suited for the detection of prostate tumors, and that a physiological relation between up-regulation and the disease symptoms and thus an inhibition of Slit1/MEGF4 is suited for the treatment of the tumor disease.

Example 2 Detection of Slit1/MEGF4 by Means of Antibodies

[0061] Polyclonal antibodies (AB) were grown against Slit1 protein (Seq.-ID 9; AB-a) and against human SLIT1/MEGF4 proteins (Seq.-ID 10; AB-b), conjugated with a carrier protein, in rabbit and affinity purified with the specific immobilized peptides.

[0062] With the above AB's, Western blots were made for the detection of Slit1 and/or MEGF4 in prostate tumor and non-malignant normal prostate epithelium cell lines and in breast tumor cell lines. For this purpose, lysates from the whole cells (wc) or of the membrane fraction (mem) were prepared, denaturated and separated by means of SDS phage gel electrophoresis. After blotting the separated proteins on a membrane and blocking unspecific protein interactions, the membrane was incubated with AB-a and/or AB-b antisera over night at 4° C. With an anti-rabbit coupled horse radish peroxidase as a secondary antibody, the specific Slit1 and/or MEGF4 bands were detected. The results are shown in FIG. 3. By means of AB-a was made the detection in all cell lines at a molecular weight of approx. 190 kD. By means of AB-b, Slit1 (approx. 190 kD) as well as MEGF4 (approx. 180 or 210 kD) became visible. The specificity of the detected proteins was verified with not shown competition experiments under addition of specific or unspecific peptides at the incubation with the AB's.

[0063] In addition to the expression shown in FIG. 3 of Slit1/MEGF4 protein in prostate tumor cell lines, an expression was found in not shown experiments in the breast tumor cell lines MaTu and MDA 231 or MDA-MB-231.

Example 3 Immunohistochemical Detection of Prostate Tumor Cells

[0064] Tissue samples from prostate tumor cells were incubated with AB-a as a primary antibody, a biotinylated secondary anti-rabbit antibody and a streptavidin-coupled horse radish peroxidase, and the coloration was performed with DAB as a chromogenic substrate (brown coloration). The counter-coloration took place with a haemalaun solution (blue coloration). Malignant and normal epithelium cells were distinguishable, the malignant cells having a strong coloration, i.e. high Slit1 content, whereas the normal epithelium cells were only moderately colored. The cuts are shown in FIG. 4, same as the negative controls performed without AB-a.

Example 4

[0065] In this example, the localization of Slit1 or MEGF4 was examined. For this purpose, PC3 (prostate tumor cell line) cells were subjected to a Facs analysis under application of AB-a and AB-b for Slit1 and for Slit1/MEGF4.

[0066] In FIG. 5a, the results for AB-a and in FIG. 5b the results for AB-b are shown. On the left-hand side, it can be seen that on the cell membrane of living, intact cells no Slit1/MEGF4 can be detected. After the permeabilization however follows a detection of the intracellularly localized proteins (right-hand side).

Example 5 RNA Inhibitors

[0067] In FIG. 6 are shown various hammerhead ribozymes cutting Slit1 or MEGF4 at the shown positions and thus inhibit the activity of any translation products or at least the quantity thereof. The respective sequences of the figure parts a to e are Seq.-ID 20 to 24.

[0068] The sequences Seq.-ID 15 and 16 are antisense sequences for Slit1 as well as for MEGF4 RNA. The sequences Seq.-ID 17, 18 and 19 are antisense sequences for Slit1, MEGF4 and tSlit1, respectively.

Example 6 Antibody Detection of Recombinant Slit

[0069] HEK293 cells were stably transfected in a conventional way with a Slit nucleic acid. Against the corresponding protein, prt87 B2 antibodies were generated in a conventional way. In FIG. 7 can be seen that Slit can be detected in the supernatant of the cultivated HEK293 cells as well as in the lysate (A). The slight height difference in tracks 2 and 3 can be put down to the different buffer conditions in the lysate or in the supernatant at the electrophoresis. In the supernatant can be detected a small protein of approx. 140 kDa (B), which might correspond to a hypothetical fission product of Slit. The results show that the antibody specifically detects Slit. Slit is secreted in the cell culture supernatant and is cut at the potential fission position.

Example 7 Binding of Slit to Heparin Agarose

[0070] Supernatant or lysate of cells from example 6 was incubated with heparin agarose. After washing the beads, the whole protein bound to the beads was eluated with a SDS-containing buffer and applied to a gel. Slit was detected by means of the antibody from example 6. From the lysate as well as from the supernatant, the complete Slit1 molecule (A) can be enriched with heparin. The shortened form from the supernatant (B) does not bind to heparin, which is in agreement with the predicted fission position.

Example 8 Isolation or Purification of Slit

[0071] Cells from example 6 were cultivated in DMEM with 10% serum, and 2,000 ml culture supernatant were obtained. This was concentrated over 50 kDa cut-off membrane to 200 ml. Therefrom samples were fed to a 20 ml heparin affinity chromatography column operated with 75% buffer A and 25% buffer B. Slit1 was then eluated with 100% buffer B from the column. The fractions 11-14 (light gray, see FIG. 9) were united and concentrated to 7 ml. The further purification was performed by a gel chromatography column (Superdex200 26/60 column), the elution taking place at 1 ml/min, and reference is made to FIG. 10. The analysis was made with a Western blot with the antibody from example 6 (FIG. 11). The fractions 21 to 28 (see FIG. 10) were united and adjusted to 2 M urea (final volume 50 ml). This sample was used after dialysis directly for QA-CIM-disk (ion exchange chromatography, 350 μl), and reference is made to FIG. 12. The elution was made with an increasing concentration of the buffer B (NaCl gradient). The fractions 20-32 were separated in a Western blot (FIG. 13), and Slit1 was detected with the antibody of example 6. Thereafter the fractions 20-25 containing Slit1 were united and analyzed in a silver gel (FIG. 14). As a result, Slit1 is detected in a purified form and with the molecular weight to be expected.

Example 9 Biological Activity of Slit Fragments

[0072] In FIG. 15, Pfam representations of the Slit1 full length proteins (I) as well as of 2 N-terminal fragments according to the sequences 25 to 28 (II and III) are shown. LLR means leucine rich repeat. EGF means epidermal growth factor domain. Laminin G means this domain. The fragment II is detectable according to example 6 (band B), and is apparently the result of an endogenic proteolytic fission. It comprises the LRR's 1-4 and the first 5 EGF. Since these protein domains are autonomously folding, also the recombinant fragment II will comprise a normal folding and a complete biological activity. Corresponding considerations apply to the fragment III with the LRR's 1-4 with its biological activity as a chemorepellent.

[0073] Legend.

[0074]FIG. 2:

[0075] Ratio tumor/normal tissue

[0076]FIG. 4:

[0077] haemalaun counter-coloration

[0078] haemalaun counter-coloration

[0079]FIG. 5a:

[0080] no coloration no fix./no perm. fix/perm.

[0081]FIG. 5b:

[0082] no fix./no perm. fix/perm.

[0083]FIG. 7:

[0084] 1: Hek293 mock transfected (empty vector)

[0085] 2: supernatant SLIT-transfected Hek293 clone 17

[0086] 3: lysate SLIT-transfected Hek293 clone 17 antibody: B2 concentration: 0.5 μg/ml

[0087]FIG. 8:

[0088] 1: supernatant SLIT-transfected Hek293 clone 17

[0089] 2: lysate SLIT-transfected Hek293 clone 17

[0090] 3: heparin precipitation supernatant SLIT-transfected Hek293 clone 17

[0091] 4: heparin precipitation lysate SLIT-transfected Hek293 clone 17

[0092] antibody: prt87 B2

[0093]FIG. 10

[0094] buffer A: PBS % buffer cB

[0095]FIG. 13

[0096] fractions 20 to 32

[0097]FIG. 14

[0098] silver gel

[0099]FIG. 15

[0100] I) full length Slit1 protein

[0101] II) Seq_ID25/Seq_ID27

[0102] III) Seq_ID26/Seq_ID28

1 28 1 5095 DNA Homo sapien 1 gcgaaacggc agaggagccg agccccctcc gcccaaggcg ccctccctcc gtccgcgcac 60 aggcgccgtc gcttggagga ccaaggtgcc tcccagcccg caggggcgcc gcgcgcaagc 120 ccgcgggctc ttcggtggct ctgccccggg actgcacctg gaggcggccc cggacgggga 180 tggtcagcgg ctgctgccgt ctggctcgcg agcgggacgc tgtgagggca ccatggcgct 240 gactcccggg tgggggtcct cggcggggcc ggtccggccg gagctctggc tgctgctgtg 300 ggcagccgcg tggcgcctgg gtgcctcggc gtgccccgcc ctctgcacct gcaccggaac 360 cacggtggac tgccacggca cggggctgca ggccattccc aagaatatac ctcggaacac 420 cgagcgcctg gaactcaatg gcaacaacat cactcggatc cataagaatg actttgcggg 480 gctcaagcag ctgcgggtgc tgcagctgat ggagaaccag attggagcag tggaacgtgg 540 tgcttttgat gacatgaagg agctggagcg gctgcgactg aaccgaaacc agctgcacat 600 gttaccggaa ctgctgttcc agaacaacca ggctttgtca agactggact tgagtgagaa 660 cgccatccag gccatcccca ggaaagcttt tcggggagct acggacctta aaaatttaca 720 gctggacaag aaccagatca gctgcattga ggaaggggcc ttccgtgctc tgcgggggct 780 ggaggtgctg accctgaaca acaacaatat caccaccatc cccgtgtcca gcttcaacca 840 tatgcccaag ctacggacct tccgcctgca ctccaaccac ctgttttgcg actgccacct 900 ggcctggctc tcgcagtggc tgaggcagcg gccaaccatc gggctcttca cccagtgctc 960 gggcccagcc agcctgcgtg gcctcaatgt ggcagaggtc cagaagagtg agttcagctg 1020 ctcaggccag ggagaagcgg ggcgcgtgcc cacctgcacc ctgtcctccg gctcctgccc 1080 ggccatgtgc acctgcagca atggcatcgt ggactgtcgt ggaaaaggcc tcactgccat 1140 cccggccaac ctgcccgaga ccatgacgga gatacgcctg gagctgaacg gcatcaagtc 1200 catccctcct ggagccttct caccctacag aaagctacgg aggatagacc tgagcaacaa 1260 tcagatcgct gagattgcac ccgacgcctt ccagggcctc cgctccctga actcgctggt 1320 cctctatgga aacaagatca cagacctccc ccgtggtgtg tttggaggcc tatacaccct 1380 acagctcctg ctcctgaatg ccaacaagat caactgcatc cggcccgatg ccttccagga 1440 cctgcagaac ctctcactgc tctccctgta tgacaacaag atccagagcc tcgccaaggg 1500 cactttcacc tccctgcggg ccatccagac tctgcacctg gcgcagaacc ctttcatttg 1560 cgactgtaac ctcaagtggc tggcagactt cctgcgcacc aatcccatcg agacgagtgg 1620 tgcccgctgt gccagtcccc ggcgcctcgc caacaagcgc atcgggcaga tcaagagcaa 1680 gaagttccgg tgctcagcca aagagcagta cttcattcca ggcacggagg attaccagct 1740 gaacagcgag tgcaacagcg acgtggtctg tccccacaag tgccgctgtg aggccaacgt 1800 ggtggagtgc tccagcctga agctcaccaa gatccctgag cgcatccccc agtccacggc 1860 agaactgcga ttgaataaca atgagatttc catcctggag gccactggga tgtttaaaaa 1920 acttacacat ctgaagaaaa tcaatctgag caacaacaag gtgtcagaaa ttgaagatgg 1980 ggccttcgag ggcgcagcct ctgtgagcga gctgcaccta actgccaacc agctggagtc 2040 catccggagc ggcatgttcc ggggtctgga tggcttgagg accctaatgc tgcggaacaa 2100 ccgcatcagc tgcatccaca acgacagctt cacgggcctg cgcaacgtcc ggctcctctc 2160 gctctacgac aaccagatca ccaccgtatc cccaggagcc ttcgacaccc tccagtccct 2220 ctccacactg aatctcctgg ccaacccttt caactgcaac tgccagctgg cctggctagg 2280 aggctggcta cggaagcgca agatcgtgac ggggaacccg cgatgccaga accctgactt 2340 tttgcggcag attcccctgc aggacgtggc cttccctgac ttcaggtgtg aggaaggcca 2400 ggaggagggg ggctgcctgc cccgcccaca gtgcccacag gagtgcgcct gcctggacac 2460 cgtggtccga tgcagcaaca agcacctgcg ggccctgccc aagggcattc ccaagaatgt 2520 cacagaactc tatttggacg ggaaccagtt cacgctggtt ccgggacagc tgtctacctt 2580 caagtacctg cagctcgtgg acctgagcaa caacaagatc agttccttaa gcaattcctc 2640 cttcaccaac atgagccagc tgaccactct gatcctcagc tacaatgccc tgcagtgcat 2700 cctgcctttg gccttccagg gactccgctc cctgcgcctg ctgtctctcc acggcaatga 2760 catctccacc ctccaagagg gcatctttgc agacgtgacc tccctgtctc acctggccat 2820 tggtgccaac cccctatact gtgactgcca cctccgctgg ctgtccagct gggtgaagac 2880 tggctacaag gaaccgggca ttgctcgttg tgctgggccc caggacatgg agggcaagct 2940 gctcctcacc acgcctgcca agaagtttga atgccaaggt cctccaacgc tggctgtcca 3000 ggccaagtgt gatctctgct tgtccagtcc gtgccagaac cagggcacct gccacaacga 3060 cccccttgag gtgtacaggt gcgcctgccc cagcggctat aagggtcgag actgtgaggt 3120 gtccctggac agctgttcca gtggcccctg tgaaaatggg ggcacctgcc atgcacagga 3180 gggcgaggat gccccgttca cgtgctcctg tcccaccggc tttgaaggac caacctgtgg 3240 ggtgaacaca gatgactgtg tggatcatgc ctgtgccaat gggggcgtct gtgtggatgg 3300 tgtgggcaac tacacctgcc agtgccccct gcagtatgag ggaaaggcct gtgagcagct 3360 ggtggacttg tgctctccgg atctgaaccc atgtcaacac gaggcccagt gtgtgggcac 3420 cccggatggg cccaggtgtg agtgcatgcc aggttatgca ggtgacaact gcagtgagaa 3480 ccaggatgac tgcagggacc accgctgcca gaatggggcc cagtgtatgg atgaagtcaa 3540 cagctactcc tgcctctgtg ctgagggcta cagtggacag ctctgtgaga tccctcccca 3600 tctgcctgcc cccaagagcc cctgtgaggg gactgagtgc cagaatgggg ccaactgtgt 3660 ggaccagggc aacaggcctg tgtgccagtg cctcccaggc ttcggtggcc ctgagtgtga 3720 gaagttgctc agtgtcaact ttgtggatcg ggacacttac ctgcagttca ctgacctgca 3780 aaactggcca cgggccaaca tcacgttgca ggtctccacg gcagaggaca atgggatcct 3840 tctgtacaac ggggacaacg accacattgc agttgagctg taccagggcc atgtgcgtgt 3900 cagctacgac ccaggcagct accccagctc tgccatctac agtgctgaga cgatcaacga 3960 tgggcaattc cacaccgttg agctggttgc ctttgaccag atggtgaatc tctccattga 4020 tggcgggagc cccatgacca tggacaactt tggcaaacat tacacgctca acagcgaggc 4080 gccactctat gtgggaggga tgcccgtgga tgtcaactca gctgccttcc gcctgtggca 4140 gatcctcaac ggcaccggct tccacggttg catccgaaac ctgtacatca acaacgagct 4200 gcaggacttc accaagacgc agatgaagcc aggcgtggtg ccaggctgcg aaccctgccg 4260 caagctctac tgcctgcatg gcatctgcca gcccaatgcc accccagggc ccatgtgcca 4320 ctgcgaggct ggctgggtgg gcctgcactg tgaccagccc gctgacggcc cctgccatgg 4380 ccacaagtgt gtccatgggc aatgcgtgcc cctcgacgct ctttcctaca gctgccagtg 4440 ccaggatggg tactcggggg cactgtgcaa ccaggccggg gccctggcag agccctgcag 4500 aggcctgcag tgcctgcatg gccactgcca ggcctcaggc accaaggggg cacactgtgt 4560 gtgtgacccc ggcttttcgg gcgagctgtg tgagcaagag tccgagtgcc ggggggaccc 4620 tgtccgggac tttcaccagg tccagagggg ctatgccatc tgccagacca cgcgccccct 4680 gtcatgggtg gagtgccggg gctcgtgccc aggccagggc tgctgccagg gccttcggct 4740 gaagcggagg aagttcacct ttgagtgcag cgatgggacc tcttttgccg aggaggtgga 4800 aaagcccacc aagtgtggct gtgccctctg cgcatagcgc tgggcgtgga caggccggtg 4860 agggcgggca aggggcccca gccgctgcag cagcggagac agtcgccagc agctgggctg 4920 gggtgcaggt catcacagga cggctcctgg gcagctgggc cctcctgggt ggggtggtgc 4980 cagagcagcc ttttaaaagc aaattgcgcc atagctgggg gcagcggggg tgggcgaggc 5040 ctgagctgcg ggctgccctc tccggaagtg ccttgcacaa ataggcgctt aataa 5095 2 7910 DNA Homo sapien 2 gcgaaacggc agaggagccg agccccctcc gcccaaggcg ccctccctcc gtccgcgcac 60 aggcgccgtc gcttggagga ccaaggtgcc tcccagcccg caggggcgcc gcgcgcaagc 120 ccgcgggctc ttcggtggct ctgccccggg actgcacctg gaggcggccc cggacgggga 180 tggtcagcgg ctgctgccgt ctggctcgcg agcgggacgc tgtgagggca ccatggcgct 240 gactcccggg tgggggtcct cggcggggcc ggtccggccg gagctctggc tgctgctgtg 300 ggcagccgcg tggcgcctgg gtgcctcggc gtgccccgcc ctctgcacct gcaccggaac 360 cacggtggac tgccacggca cggggctgca ggccattccc aagaatatac ctcggaacac 420 cgagcgcctg gaactcaatg gcaacaacat cactcggatc cataagaatg actttgcggg 480 gctcaagcag ctgcgggtgc tgcagctgat ggagaaccag attggagcag tggaacgtgg 540 tgcttttgat gacatgaagg agctggagcg gctgcgactg aaccgaaacc agctgcacat 600 gttaccggaa ctgctgttcc agaacaacca ggctttgtca agactggact tgagtgagaa 660 cgccatccag gccatcccca ggaaagcttt tcggggagct acggacctta aaaatttaca 720 gctggacaag aaccagatca gctgcattga ggaaggggcc ttccgtgctc tgcgggggct 780 ggaggtgctg accctgaaca acaacaatat caccaccatc cccgtgtcca gcttcaacca 840 tatgcccaag ctacggacct tccgcctgca ctccaaccac ctgttttgcg actgccacct 900 ggcctggctc tcgcagtggc tgaggcagcg gccaaccatc gggctcttca cccagtgctc 960 gggcccagcc agcctgcgtg gcctcaatgt ggcagaggtc cagaagagtg agttcagctg 1020 ctcaggccag ggagaagcgg ggcgcgtgcc cacctgcacc ctgtcctccg gctcctgccc 1080 ggccatgtgc acctgcagca atggcatcgt ggactgtcgt ggaaaaggcc tcactgccat 1140 cccggccaac ctgcccgaga ccatgacgga gatacgcctg gagctgaacg gcatcaagtc 1200 catccctcct ggagccttct caccctacag aaagctacgg aggatagacc tgagcaacaa 1260 tcagatcgct gagattgcac ccgacgcctt ccagggcctc cgctccctga actcgctggt 1320 cctctatgga aacaagatca cagacctccc ccgtggtgtg tttggaggcc tatacaccct 1380 acagctcctg ctcctgaatg ccaacaagat caactgcatc cggcccgatg ccttccagga 1440 cctgcagaac ctctcactgc tctccctgta tgacaacaag atccagagcc tcgccaaggg 1500 cactttcacc tccctgcggg ccatccagac tctgcacctg gcgcagaacc ctttcatttg 1560 cgactgtaac ctcaagtggc tggcagactt cctgcgcacc aatcccatcg agacgagtgg 1620 tgcccgctgt gccagtcccc ggcgcctcgc caacaagcgc atcgggcaga tcaagagcaa 1680 gaagttccgg tgctcagcca aagagcagta cttcattcca ggcacggagg attaccagct 1740 gaacagcgag tgcaacagcg acgtggtctg tccccacaag tgccgctgtg aggccaacgt 1800 ggtggagtgc tccagcctga agctcaccaa gatccctgag cgcatccccc agtccacggc 1860 agaactgcga ttgaataaca atgagatttc catcctggag gccactggga tgtttaaaaa 1920 acttacacat ctgaagaaaa tcaatctgag caacaacaag gtgtcagaaa ttgaagatgg 1980 ggccttcgag ggcgcagcct ctgtgagcga gctgcaccta actgccaacc agctggagtc 2040 catccggagc ggcatgttcc ggggtctgga tggcttgagg accctaatgc tgcggaacaa 2100 ccgcatcagc tgcatccaca acgacagctt cacgggcctg cgcaacgtcc ggctcctctc 2160 gctctacgac aaccagatca ccaccgtatc cccaggagcc ttcgacaccc tccagtccct 2220 ctccacactg aatctcctgg ccaacccttt caactgcaac tgccagctgg cctggctagg 2280 aggctggcta cggaagcgca agatcgtgac ggggaacccg cgatgccaga accctgactt 2340 tttgcggcag attcccctgc aggacgtggc cttccctgac ttcaggtgtg aggaaggcca 2400 ggaggagggg ggctgcctgc cccgcccaca gtgcccacag gagtgcgcct gcctggacac 2460 cgtggtccga tgcagcaaca agcacctgcg ggccctgccc aagggcattc ccaagaatgt 2520 cacagaactc tatttggacg ggaaccagtt cacgctggtt ccgggacagc tgtctacctt 2580 caagtacctg cagctcgtgg acctgagcaa caacaagatc agttccttaa gcaattcctc 2640 cttcaccaac atgagccagc tgaccactct gatcctcagc tacaatgccc tgcagtgcat 2700 cccgcctttg gccttccagg gactccgctc cctgcgcctg ctgtctctcc acggcaatga 2760 catctccacc ctccaagagg gcatctttgc agacgtgacc tccctgtctc acctggccat 2820 tggtgccaac cccctatact gtgactgcca cctccgctgg ctgtccagct gggtgaagac 2880 tggctacaag gaaccgggca ttgctcgttg tgctgggccc caggacatgg agggcaagct 2940 gctcctcacc acgcctgcca agaagtttga atgccaaggt cctccaacgc tggctgtcca 3000 ggccaagtgt gatctctgct tgtccagtcc gtgccagaac cagggcacct gccacaacga 3060 cccccttgag gtgtacaggt gcgcctgccc cagcggctat aagggtcgag actgtgaggt 3120 gtccctggac agctgttcca gtggcccctg tgaaaatggg ggcacctgcc atgcacagga 3180 gggcgaggat gccccgttca cgtgctcctg tcccaccggc tttgaaggac caacctgtgg 3240 ggtgaacaca gatgactgtg tggatcatgc ctgtgccaat gggggcgtct gtgtggatgg 3300 tgtgggcaac tacacctgcc agtgccccct gcagtatgag ggaaaggcct gtgagcagct 3360 ggtggacttg tgctctccgg atctgaaccc atgtcaacac gaggcccagt gtgtgggcac 3420 cccggatggg cccaggtgtg agtgcatgcc aggttatgca ggtgacaact gcagtgagaa 3480 ccaggatgac tgcagggacc accgctgcca gaatggggcc cagtgtatgg atgaagtcaa 3540 cagctactcc tgcctctgtg ctgagggcta cagtggacag ctctgtgaga tccctcccca 3600 tctgcctgcc cccaagagcc cctgtgaggg gactgagtgc cagaatgggg ccaactgtgt 3660 ggaccagggc aacaggcctg tgtgccagtg cctcccaggc ttcggtggcc ctgagtgtga 3720 gaagttgctc agtgtcaact ttgtggatcg ggacacttac ctgcagttca ctgacctgca 3780 aaactggcca cgggccaaca tcacgttgca ggtctccacg gcagaggaca atgggatcct 3840 tctgtacaac ggggacaacg accacattgc agttgagctg taccagggcc atgtgcgtgt 3900 cagctacgac ccaggcagct accccagctc tgccatctac agtgctgaga cgatcaacga 3960 tgggcaattc cacaccgttg agctggttgc ctttgaccag atggtgaatc tctccattga 4020 tggcgggagc cccatgacca tggacaactt tggcaaacat tacacgctca acagcgaggc 4080 gccactctat gtgggaggga tgcccgtgga tgtcaactca gctgccttcc gcctgtggca 4140 gatcctcaac ggcaccggct tccacggttg catccgaaac ctgtacatca acaacgagct 4200 gcaggacttc accaagacgc agatgaagcc aggcgtggtg ccaggctgcg aaccctgccg 4260 caagctctac tgcctgcatg gcatctgcca gcccaatgcc accccagggc ccatgtgcca 4320 ctgcgaggct ggctgggtgg gcctgcactg tgaccagccc gctgacggcc cctgccatgg 4380 ccacaagtgt gtccatgggc aatgcgtgcc cctcgacgct ctttcctaca gctgccagtg 4440 ccaggatggg tactcggggg cactgtgcaa ccaggccggg gccctggcag agccctgcag 4500 aggcctgcag tgcctgcatg gccactgcca ggcctcaggc accaaggggg cacactgtgt 4560 gtgtgacccc ggcttttcgg gcgagctgtg tgagcaagag tccgagtgcc ggggggaccc 4620 tgtccgggac tttcaccagg tccagagggg ctatgccatc tgccagacca cgcgccccct 4680 gtcatgggtg gagtgccggg gctcgtgccc aggccagggc tgctgccagg gccttcggct 4740 gaagcggagg aagttcacct ttgagtgcag cgatgggacc tcttttgccg aggaggtgga 4800 aaagcccacc aagtgtggct gtgccctctg cgcatagcgc tgggcgtgga caggccggtg 4860 agggcgggca aggggcccca gccgctgcag cagcggagac agtcgccagc agctgggctg 4920 gggtgcaggt catcacagga cggctcctgg gcagctgggc cctcctgggt ggggtggtgc 4980 cagagcagcc ttttaaaagc aaattgcgcc atagctgggg gcagcggggg tgggcgaggc 5040 ctgagctgcg ggctgccctc tccggaagtg ccttgcacaa ataggcgctt aataaatatt 5100 tgttgagtga atgtgtgcgt gaggtcaggc caagaagtgc agaacgatga cacccctcct 5160 tacctgctat ctgaatctgg agaagaaaaa tgacagcctt ccaaaccaac ccttcccttt 5220 ggcctgtggc ccaggctggc ttggaactgg gtctgtggcc ccagaagcct cttacccctc 5280 tgcgggcaac catgaagtac tgtcagcctc cccgggaagc cagcctggtt cattctgctg 5340 ctacagaatc tgctggtggt aggccaggct ctggagcggg ggtgccgcct cctgctggcc 5400 agggagggtc ggacccttgc cccctgggct gactggcagc tctgcagcca cggcttggga 5460 acgaggctgt gggtggaggt ggttcttagg accaggcctc tgaatcctaa agttctagca 5520 tgactactgt agctgcgagg gcttatgtgg aggaaacagt cacaggggct gctcagggtg 5580 gcagacccca ctaaagaggg cagagggttc tttgctctag ataaacaaac atcatctgcc 5640 tccagacact ggccacagta ggagtattgg tcctgggctt ccccagccac cagtcagcca 5700 caagctgtcg gtgacctatt ggtagaggga ctgggtgtga gggtctgggc cagggtgctt 5760 gacctgggag cagctggttc agagtccttc acaccgcagg ccagtaggga gcagtggaag 5820 ggacagtgct ccaggcattg ggaagtccct gctggctcta tcactcgggg caaacttctc 5880 cccacctggg ccttgggttc ttcagctata aaatggccag aggtgggggg cgggatgact 5940 aaaggaacag tgcagactcc cccactgtgg tcttgggagg ccagaggagt tagaagacct 6000 atctatctat ctatctatct acattgatca catcaaaagt atttatgtgc ctaacccggg 6060 gctggggatt gtggacgttc tggcctaatg gacagatgtg aactcatccc agagcatcgc 6120 aggaatgacc aggatgcccg ggaagagttg agctgagtgg gggctccagc cacagacagc 6180 ggcccaggcc agggagttgc tggcaacgaa ggagccagtg gtggaagaag aagaggccct 6240 gaatatacga ttgcctgccc acgttgtctt ctcttccata cacagtgaaa atgtagaaag 6300 atggtttgtg aggccaaact gtgaatgggc taaagggagg caaagttgca ctctccttcc 6360 ccagagggct caccaagagg gcacaccccc gggggttctg gtgggcaacg ggggtgagca 6420 tgtccctgcc ctggctccct ccatctgtga ccaggaggca tggctgggtg tatgttcagg 6480 tgaggctcag agtggcattg tgtccctgtc ccctgcccag ggcagtgagg ggagcccttg 6540 atgctgatta gaaggctaga actggggtag aggtgcctgg catgtctcat gccatgggga 6600 ctcaatctag caactgtgag tcctggggtc cctgtgatgg gaagagggca gtgccctgcc 6660 caatgtggca ggtgtcctca tggcaggatc tgcccctcac cagggggctg ggatctactt 6720 gcttggagct ctgagcaagg ccacaatgcc cgcccccacc cccaagtaga ctgcagcctg 6780 ggcctcatgg ggcttctccc aggcccacat ggcatccctc tctgagtttc caggccaccg 6840 tgggaccctg cagagcatct gcaccgggct ggatagggca gaaaagctca agggcagcta 6900 gcttgcctct tccctggaag aaaggtgctc tgggactcac caaccctgag aaagatagct 6960 ttcctggcca ccaccattcc ccaccaccct ggagaagcca attcccaggc ttgaagggca 7020 ctggctggca ggaggcctct tcattctgca ggaggtggaa aggacacctg tagacaggtg 7080 atgctcaccc ctcacctggc gccatggggc tgggaggtga gcggctggca tgtttgttcc 7140 tagggagcac catgtgagct taaggctccc ctgaccggcc ccaccacatg gcccagcctc 7200 ctagcacagc agcgctgacc tcagtgcagt ctgaggattg gaatccacca tgagatgatg 7260 tgagagctgt gtgccccagg atcaactttt tctccaactt ggccatcagc cagcgagttg 7320 ctaaggacct gagtcagcac tcacgttgcc tattcacact ccgcttgaaa gtccggaagg 7380 tggctactgc aaaatcaccc ctctgagaag tcctctctcc acatcttgtc cccctttgtg 7440 aagaccccta gttcgctctg cattttaggc atgaagagat acagcagggt gcgtccggag 7500 ggagctgtgg ccttgcaaca ccactggcaa cagggccggg gctcccggtg aaggtgtcag 7560 gaagtggaaa aggctggact ttgtctcctc tttgcctgct ggtagcctaa ccgcaaaagt 7620 atctctttat acagaatact tacagattct aatatatatt tgtatttcat tttgttacag 7680 tatttttata tgttaaagtc aacatccagc gtcttgtttt gcctttcaga tgctatgtgg 7740 tcgtggcacg ttttgttggg ggtttctgta gtcgtcttgt ttggatcaac tcctagaggc 7800 tggtttagaa caggcccatg agggagctgc acctgccctg gaagtattgt tttagactat 7860 gtcgatattg tctgttgtct tccatgtgaa catgacattg agtcactctg 7910 3 5902 DNA Homo sapien 3 gcgaaacggc agaggagccg agccccctcc gcccaaggcg ccctccctcc gtccgcgcac 60 aggcgccgtc gcttggagga ccaaggtgcc tcccagcccg caggggcgcc gcgcgcaagc 120 ccgcgggctc ttcggtggct ctgccccggg actgcacctg gaggcggccc cggacgggga 180 tggtcagcgg ctgctgccgt ctggctcgcg agcgggacgc tgtgagggca ccatggcgct 240 gactcccggg tgggggtcct cggcggggcc ggtccggccg gagctctggc tgctgctgtg 300 ggcagccgcg tggcgcctgg gtgcctcggc gtgccccgcc ctctgcacct gcaccggaac 360 cacggtggac tgccacggca cggggctgca ggccattccc aagaatatac ctcggaacac 420 cgagcgcctg gaactcaatg gcaacaacat cactcggatc cataagaatg actttgcggg 480 gctcaagcag ctgcgggtgc tgcagctgat ggagaaccag attggagcag tggaacgtgg 540 tgcttttgat gacatgaagg agctggagcg gctgcgactg aaccgaaacc agctgcacat 600 gttaccggaa ctgctgttcc agaacaacca ggctttgtca agactggact tgagtgagaa 660 cgccatccag gccatcccca ggaaagcttt tcggggagct acggacctta aaaatttaca 720 gctggacaag aaccagatca gctgcattga ggaaggggcc ttccgtgctc tgcgggggct 780 ggaggtgctg accctgaaca acaacaatat caccaccatc cccgtgtcca gcttcaacca 840 tatgcccaag ctacggacct tccgcctgca ctccaaccac ctgttttgcg actgccacct 900 ggcctggctc tcgcagtggc tgaggcagcg gccaaccatc gggctcttca cccagtgctc 960 gggcccagcc agcctgcgtg gcctcaatgt ggcagaggtc cagaagagtg agttcagctg 1020 ctcaggccag ggagaagcgg ggcgcgtgcc cacctgcacc ctgtcctccg gctcctgccc 1080 ggccatgtgc acctgcagca atggcatcgt ggactgtcgt ggaaaaggcc tcactgccat 1140 cccggccaac ctgcccgaga ccatgacgga gatacgcctg gagctgaacg gcatcaagtc 1200 catccctcct ggagccttct caccctacag aaagctacgg aggatagacc tgagcaacaa 1260 tcagatcgct gagattgcac ccgacgcctt ccagggcctc cgctccctga actcgctggt 1320 cctctatgga aacaagatca cagacctccc ccgtggtgtg tttggaggcc tatacaccct 1380 acagctcctg ctcctgaatg ccaacaagat caactgcatc cggcccgatg ccttccagga 1440 cctgcagaac ctctcactgc tctccctgta tgacaacaag atccagagcc tcgccaaggg 1500 cactttcacc tccctgcggg ccatccagac tctgcacctg gcgcagaacc ctttcatttg 1560 cgactgtaac ctcaagtggc tggcagactt cctgcgcacc aatcccatcg agacgagtgg 1620 tgcccgctgt gccagtcccc ggcgcctcgc caacaagcgc atcgggcaga tcaagagcaa 1680 gaagttccgg tgctcagcca aagagcagta cttcattcca ggcacggagg attaccagct 1740 gaacagcgag tgcaacagcg acgtggtctg tccccacaag tgccgctgtg aggccaacgt 1800 ggtggagtgc tccagcctga agctcaccaa gatccctgag cgcatccccc agtccacggc 1860 agaactgcga ttgaataaca atgagatttc catcctggag gccactggga tgtttaaaaa 1920 acttacacat ctgaagaaaa tcaatctgag caacaacaag gtgtcagaaa ttgaagatgg 1980 ggccttcgag ggcgcagcct ctgtgagcga gctgcaccta actgccaacc agctggagtc 2040 catccggagc ggcatgttcc ggggtctgga tggcttgagg accctaatgc tgcggaacaa 2100 ccgcatcagc tgcatccaca acgacagctt cacgggcctg cgcaacgtcc ggctcctctc 2160 gctctacgac aaccagatca ccaccgtatc cccaggagcc ttcgacaccc tccagtccct 2220 ctccacactg aatctcctgg ccaacccttt caactgcaac tgccagctgg cctggctagg 2280 aggctggcta cggaagcgca agatcgtgac ggggaacccg cgatgccaga accctgactt 2340 tttgcggcag attcccctgc aggacgtggc cttccctgac ttcaggtgtg aggaaggcca 2400 ggaggagggg ggctgcctgc cccgcccaca gtgcccacag gagtgcgcct gcctggacac 2460 cgtggtccga tgcagcaaca agcacctgcg ggccctgccc aagggcattc ccaagaatgt 2520 cacagaactc tatttggacg ggaaccagtt cacgctggtt ccgggacagc tgtctacctt 2580 caagtacctg cagctcgtgg acctgagcaa caacaagatc agttccttaa gcaattcctc 2640 cttcaccaac atgagccagc tgaccactct gatcctcagc tacaatgccc tgcagtgcat 2700 cccgcctttg gccttccagg gactccgctc cctgcgcctg ctgtctctcc acggcaatga 2760 catctccacc ctccaagagg gcatctttgc agacgtgacc tccctgtctc acctggccat 2820 tggtgccaac cccctatact gtgactgcca cctccgctgg ctgtccagct gggtgaagac 2880 tggctacaag gaaccgggca ttgctcgttg tgctgggccc caggacatgg agggcaagct 2940 gctcctcacc acgcctgcca agaagtttga atgccaaggt cctccaacgc tggctgtcca 3000 ggccaagtgt gatctctgct tgtccagtcc gtgccagaac cagggcacct gccacaacga 3060 cccccttgag gtgtacaggt gcgcctgccc cagcggctat aagggtcgag actgtgaggt 3120 gtccctggac agctgttcca gtggcccctg tgaaaatggg ggcacctgcc atgcacagga 3180 gggcgaggat gccccgttca cgtgctcctg tcccaccggc tttgaaggac caacctgtgg 3240 ggtgaacaca gatgactgtg tggatcatgc ctgtgccaat gggggcgtct gtgtggatgg 3300 tgtgggcaac tacacctgcc agtgccccct gcagtatgag ggaaaggcct gtgagcagct 3360 ggtggacttg tgctctccgg atctgaaccc atgtcaacac gaggcccagt gtgtgggcac 3420 cccggatggg cccaggtgtg agtgcatgcc aggttatgca ggtgacaact gcagtgagaa 3480 ccaggatgac tgcagggacc accgctgcca gaatggggcc cagtgtatgg atgaagtcaa 3540 cagctactcc tgcctctgtg ctgagggcta cagtggacag ctctgtgaga tccctcccca 3600 tctgcctgcc cccaagagcc cctgtgaggg gactgagtgc cagaatgggg ccaactgtgt 3660 ggaccagggc aacaggcctg tgtgccagtg cctcccaggc ttcggtggcc ctgagtgtga 3720 gaagttgctc agtgtcaact ttgtggatcg ggacacttac ctgcagttca ctgacctgca 3780 aaactggcca cgggccaaca tcacgttgca ggtctccacg gcagaggaca atgggatcct 3840 tctgtacaac ggggacaacg accacattgc agttgagctg taccagggcc atgtgcgtgt 3900 cagctacgac ccaggcagct accccagctc tgccatctac agtgctgaga cgatcaacga 3960 tgggcaattc cacaccgttg agctggttgc ctttgaccag atggtgaatc tctccattga 4020 tggcgggagc cccatgacca tggacaactt tggcaaacat tacacgctca acagcgaggc 4080 gccactctat gtgggaggga tgcccgtgga tgtcaactca gctgccttcc gcctgtggca 4140 gatcctcaac ggcaccggct tccacggttg catccgaaac ctgtacatca acaacgagct 4200 gcaggacttc accaagacgc agatgaagcc aggcgtggtg ccaggctgcg aaccctgccg 4260 caagctctac tgcctgcatg gcatctgcca gcccaatgcc accccagggc ccatgtgcca 4320 ctgcgaggct ggctgggtgg gcctgcactg tgaccagccc gctgacggcc cctgccatgg 4380 ccacaagtgt gtccatgggc aatgcgtgcc cctcgacgct ctttcctaca gctgccagtg 4440 ccaggatggg tactcggggg cactgtgcaa ccaggccggg gccctggcag agccctgcag 4500 aggcctgcag tgcctgcatg gccactgcca ggcctcaggc accaaggggg cacactgtgt 4560 gtgtgacccc ggcttttcgg gcgagctgtg tgagcaaggt caggggcccc cctcctgacg 4620 tgccctcccc agggtccccc acaaattgct ttagcaattt gactcttcct cccagtctcg 4680 gcagcccttc tgtcccttcc cagccctgta ccatgggcta ctatggggct ttcagagtcc 4740 ctccaccctc tgggcactgc tcccaatctc tcctggccca gtttgccctg cagctccctt 4800 attcagggta tgcgcctctt ctggctgggg tctctccttg cagaagagac cacccagggt 4860 aacagctcct ggcccaacct ctgcctcttg gccccatcac ctcatgacct gggagcggca 4920 gcaggaagtc cgagggttgg ggactccttc ccaggccctc cctggcctgc ttgaccaaga 4980 tggcttctgc tggaatccgg actgctaagg ctgggcaggg agaagctgga gaaacccaga 5040 actcaggcac cttaagggtc ccctaggcta tcccctcccc agcatgaatc cttttcataa 5100 tgttattgcc cccggggcct ccagcctctc ttgcacgcct ctagcaatgg ggaccccccc 5160 tccctccagc agttcagtct gtcctggagg gccctgacgc taggaccaga ctgtaggccc 5220 tgggaggaag cttgtgcatg tcagtgggag gcggaagtat gctggggaca gaggtggggt 5280 ctgagagcca aaggatccac cccacagatg ctgccctcct cctcctcttc ctcctgcctc 5340 cctggaggca gcagctcacc catgggtgtg ccctgaggct ttctcttggt gtctgtccca 5400 tccagagtcc gagtgccggg gggaccctgt ccgggacttt caccaggtcc agaggggcta 5460 tgccatctgc cagaccacgc gccccctgtc atgggtggag tgccggggct cgtgcccagg 5520 ccagggctgc tgccagggcc ttcggctgaa gcggaggaag ttcacctttg agtgcagcga 5580 tgggacctct tttgccgagg aggtggaaaa gcccaccaag tgtggctgtg ccctctgcgc 5640 atagcgctgg gcgtggacag gccggtgagg gcgggcaagg ggccccagcc gctgcagcag 5700 cggagacagt cgccagcagc tgggctgggg tgcaggtcat cacaggacgg ctcctgggca 5760 gctgggccct cctgggtggg gtggtgccag agcagccttt taaaagcaaa ttgcgccata 5820 gctgggggca gcgggggtgg gcgaggcctg agctgcgggc tgccctctcc ggaagtgcct 5880 tgcacaaata ggcgcttaat aa 5902 4 8717 DNA Homo sapien 4 gcgaaacggc agaggagccg agccccctcc gcccaaggcg ccctccctcc gtccgcgcac 60 aggcgccgtc gcttggagga ccaaggtgcc tcccagcccg caggggcgcc gcgcgcaagc 120 ccgcgggctc ttcggtggct ctgccccggg actgcacctg gaggcggccc cggacgggga 180 tggtcagcgg ctgctgccgt ctggctcgcg agcgggacgc tgtgagggca ccatggcgct 240 gactcccggg tgggggtcct cggcggggcc ggtccggccg gagctctggc tgctgctgtg 300 ggcagccgcg tggcgcctgg gtgcctcggc gtgccccgcc ctctgcacct gcaccggaac 360 cacggtggac tgccacggca cggggctgca ggccattccc aagaatatac ctcggaacac 420 cgagcgcctg gaactcaatg gcaacaacat cactcggatc cataagaatg actttgcggg 480 gctcaagcag ctgcgggtgc tgcagctgat ggagaaccag attggagcag tggaacgtgg 540 tgcttttgat gacatgaagg agctggagcg gctgcgactg aaccgaaacc agctgcacat 600 gttaccggaa ctgctgttcc agaacaacca ggctttgtca agactggact tgagtgagaa 660 cgccatccag gccatcccca ggaaagcttt tcggggagct acggacctta aaaatttaca 720 gctggacaag aaccagatca gctgcattga ggaaggggcc ttccgtgctc tgcgggggct 780 ggaggtgctg accctgaaca acaacaatat caccaccatc cccgtgtcca gcttcaacca 840 tatgcccaag ctacggacct tccgcctgca ctccaaccac ctgttttgcg actgccacct 900 ggcctggctc tcgcagtggc tgaggcagcg gccaaccatc gggctcttca cccagtgctc 960 gggcccagcc agcctgcgtg gcctcaatgt ggcagaggtc cagaagagtg agttcagctg 1020 ctcaggccag ggagaagcgg ggcgcgtgcc cacctgcacc ctgtcctccg gctcctgccc 1080 ggccatgtgc acctgcagca atggcatcgt ggactgtcgt ggaaaaggcc tcactgccat 1140 cccggccaac ctgcccgaga ccatgacgga gatacgcctg gagctgaacg gcatcaagtc 1200 catccctcct ggagccttct caccctacag aaagctacgg aggatagacc tgagcaacaa 1260 tcagatcgct gagattgcac ccgacgcctt ccagggcctc cgctccctga actcgctggt 1320 cctctatgga aacaagatca cagacctccc ccgtggtgtg tttggaggcc tatacaccct 1380 acagctcctg ctcctgaatg ccaacaagat caactgcatc cggcccgatg ccttccagga 1440 cctgcagaac ctctcactgc tctccctgta tgacaacaag atccagagcc tcgccaaggg 1500 cactttcacc tccctgcggg ccatccagac tctgcacctg gcgcagaacc ctttcatttg 1560 cgactgtaac ctcaagtggc tggcagactt cctgcgcacc aatcccatcg agacgagtgg 1620 tgcccgctgt gccagtcccc ggcgcctcgc caacaagcgc atcgggcaga tcaagagcaa 1680 gaagttccgg tgctcagcca aagagcagta cttcattcca ggcacggagg attaccagct 1740 gaacagcgag tgcaacagcg acgtggtctg tccccacaag tgccgctgtg aggccaacgt 1800 ggtggagtgc tccagcctga agctcaccaa gatccctgag cgcatccccc agtccacggc 1860 agaactgcga ttgaataaca atgagatttc catcctggag gccactggga tgtttaaaaa 1920 acttacacat ctgaagaaaa tcaatctgag caacaacaag gtgtcagaaa ttgaagatgg 1980 ggccttcgag ggcgcagcct ctgtgagcga gctgcaccta actgccaacc agctggagtc 2040 catccggagc ggcatgttcc ggggtctgga tggcttgagg accctaatgc tgcggaacaa 2100 ccgcatcagc tgcatccaca acgacagctt cacgggcctg cgcaacgtcc ggctcctctc 2160 gctctacgac aaccagatca ccaccgtatc cccaggagcc ttcgacaccc tccagtccct 2220 ctccacactg aatctcctgg ccaacccttt caactgcaac tgccagctgg cctggctagg 2280 aggctggcta cggaagcgca agatcgtgac ggggaacccg cgatgccaga accctgactt 2340 tttgcggcag attcccctgc aggacgtggc cttccctgac ttcaggtgtg aggaaggcca 2400 ggaggagggg ggctgcctgc cccgcccaca gtgcccacag gagtgcgcct gcctggacac 2460 cgtggtccga tgcagcaaca agcacctgcg ggccctgccc aagggcattc ccaagaatgt 2520 cacagaactc tatttggacg ggaaccagtt cacgctggtt ccgggacagc tgtctacctt 2580 caagtacctg cagctcgtgg acctgagcaa caacaagatc agttccttaa gcaattcctc 2640 cttcaccaac atgagccagc tgaccactct gatcctcagc tacaatgccc tgcagtgcat 2700 cccgcctttg gccttccagg gactccgctc cctgcgcctg ctgtctctcc acggcaatga 2760 catctccacc ctccaagagg gcatctttgc agacgtgacc tccctgtctc acctggccat 2820 tggtgccaac cccctatact gtgactgcca cctccgctgg ctgtccagct gggtgaagac 2880 tggctacaag gaaccgggca ttgctcgttg tgctgggccc caggacatgg agggcaagct 2940 gctcctcacc acgcctgcca agaagtttga atgccaaggt cctccaacgc tggctgtcca 3000 ggccaagtgt gatctctgct tgtccagtcc gtgccagaac cagggcacct gccacaacga 3060 cccccttgag gtgtacaggt gcgcctgccc cagcggctat aagggtcgag actgtgaggt 3120 gtccctggac agctgttcca gtggcccctg tgaaaatggg ggcacctgcc atgcacagga 3180 gggcgaggat gccccgttca cgtgctcctg tcccaccggc tttgaaggac caacctgtgg 3240 ggtgaacaca gatgactgtg tggatcatgc ctgtgccaat gggggcgtct gtgtggatgg 3300 tgtgggcaac tacacctgcc agtgccccct gcagtatgag ggaaaggcct gtgagcagct 3360 ggtggacttg tgctctccgg atctgaaccc atgtcaacac gaggcccagt gtgtgggcac 3420 cccggatggg cccaggtgtg agtgcatgcc aggttatgca ggtgacaact gcagtgagaa 3480 ccaggatgac tgcagggacc accgctgcca gaatggggcc cagtgtatgg atgaagtcaa 3540 cagctactcc tgcctctgtg ctgagggcta cagtggacag ctctgtgaga tccctcccca 3600 tctgcctgcc cccaagagcc cctgtgaggg gactgagtgc cagaatgggg ccaactgtgt 3660 ggaccagggc aacaggcctg tgtgccagtg cctcccaggc ttcggtggcc ctgagtgtga 3720 gaagttgctc agtgtcaact ttgtggatcg ggacacttac ctgcagttca ctgacctgca 3780 aaactggcca cgggccaaca tcacgttgca ggtctccacg gcagaggaca atgggatcct 3840 tctgtacaac ggggacaacg accacattgc agttgagctg taccagggcc atgtgcgtgt 3900 cagctacgac ccaggcagct accccagctc tgccatctac agtgctgaga cgatcaacga 3960 tgggcaattc cacaccgttg agctggttgc ctttgaccag atggtgaatc tctccattga 4020 tggcgggagc cccatgacca tggacaactt tggcaaacat tacacgctca acagcgaggc 4080 gccactctat gtgggaggga tgcccgtgga tgtcaactca gctgccttcc gcctgtggca 4140 gatcctcaac ggcaccggct tccacggttg catccgaaac ctgtacatca acaacgagct 4200 gcaggacttc accaagacgc agatgaagcc aggcgtggtg ccaggctgcg aaccctgccg 4260 caagctctac tgcctgcatg gcatctgcca gcccaatgcc accccagggc ccatgtgcca 4320 ctgcgaggct ggctgggtgg gcctgcactg tgaccagccc gctgacggcc cctgccatgg 4380 ccacaagtgt gtccatgggc aatgcgtgcc cctcgacgct ctttcctaca gctgccagtg 4440 ccaggatggg tactcggggg cactgtgcaa ccaggccggg gccctggcag agccctgcag 4500 aggcctgcag tgcctgcatg gccactgcca ggcctcaggc accaaggggg cacactgtgt 4560 gtgtgacccc ggcttttcgg gcgagctgtg tgagcaaggt caggggcccc cctcctgacg 4620 tgccctcccc agggtccccc acaaattgct ttagcaattt gactcttcct cccagtctcg 4680 gcagcccttc tgtcccttcc cagccctgta ccatgggcta ctatggggct ttcagagtcc 4740 ctccaccctc tgggcactgc tcccaatctc tcctggccca gtttgccctg cagctccctt 4800 attcagggta tgcgcctctt ctggctgggg tctctccttg cagaagagac cacccagggt 4860 aacagctcct ggcccaacct ctgcctcttg gccccatcac ctcatgacct gggagcggca 4920 gcaggaagtc cgagggttgg ggactccttc ccaggccctc cctggcctgc ttgaccaaga 4980 tggcttctgc tggaatccgg actgctaagg ctgggcaggg agaagctgga gaaacccaga 5040 actcaggcac cttaagggtc ccctaggcta tcccctcccc agcatgaatc cttttcataa 5100 tgttattgcc cccggggcct ccagcctctc ttgcacgcct ctagcaatgg ggaccccccc 5160 tccctccagc agttcagtct gtcctggagg gccctgacgc taggaccaga ctgtaggccc 5220 tgggaggaag cttgtgcatg tcagtgggag gcggaagtat gctggggaca gaggtggggt 5280 ctgagagcca aaggatccac cccacagatg ctgccctcct cctcctcttc ctcctgcctc 5340 cctggaggca gcagctcacc catgggtgtg ccctgaggct ttctcttggt gtctgtccca 5400 tccagagtcc gagtgccggg gggaccctgt ccgggacttt caccaggtcc agaggggcta 5460 tgccatctgc cagaccacgc gccccctgtc atgggtggag tgccggggct cgtgcccagg 5520 ccagggctgc tgccagggcc ttcggctgaa gcggaggaag ttcacctttg agtgcagcga 5580 tgggacctct tttgccgagg aggtggaaaa gcccaccaag tgtggctgtg ccctctgcgc 5640 atagcgctgg gcgtggacag gccggtgagg gcgggcaagg ggccccagcc gctgcagcag 5700 cggagacagt cgccagcagc tgggctgggg tgcaggtcat cacaggacgg ctcctgggca 5760 gctgggccct cctgggtggg gtggtgccag agcagccttt taaaagcaaa ttgcgccata 5820 gctgggggca gcgggggtgg gcgaggcctg agctgcgggc tgccctctcc ggaagtgcct 5880 tgcacaaata ggcgcttaat aaatatttgt tgagtgaatg tgtgcgtgag gtcaggccaa 5940 gaagtgcaga acgatgacac ccctccttac ctgctatctg aatctggaga agaaaaatga 6000 cagccttcca aaccaaccct tccctttggc ctgtggccca ggctggcttg gaactgggtc 6060 tgtggcccca gaagcctctt acccctctgc gggcaaccat gaagtactgt cagcctcccc 6120 gggaagccag cctggttcat tctgctgcta cagaatctgc tggtggtagg ccaggctctg 6180 gagcgggggt gccgcctcct gctggccagg gagggtcgga cccttgcccc ctgggctgac 6240 tggcagctct gcagccacgg cttgggaacg aggctgtggg tggaggtggt tcttaggacc 6300 aggcctctga atcctaaagt tctagcatga ctactgtagc tgcgagggct tatgtggagg 6360 aaacagtcac aggggctgct cagggtggca gaccccacta aagagggcag agggttcttt 6420 gctctagata aacaaacatc atctgcctcc agacactggc cacagtagga gtattggtcc 6480 tgggcttccc cagccaccag tcagccacaa gctgtcggtg acctattggt agagggactg 6540 ggtgtgaggg tctgggccag ggtgcttgac ctgggagcag ctggttcaga gtccttcaca 6600 ccgcaggcca gtagggagca gtggaaggga cagtgctcca ggcattggga agtccctgct 6660 ggctctatca ctcggggcaa acttctcccc acctgggcct tgggttcttc agctataaaa 6720 tggccagagg tggggggcgg gatgactaaa ggaacagtgc agactccccc actgtggtct 6780 tgggaggcca gaggagttag aagacctatc tatctatcta tctatctaca ttgatcacat 6840 caaaagtatt tatgtgccta acccggggct ggggattgtg gacgttctgg cctaatggac 6900 agatgtgaac tcatcccaga gcatcgcagg aatgaccagg atgcccggga agagttgagc 6960 tgagtggggg ctccagccac agacagcggc ccaggccagg gagttgctgg caacgaagga 7020 gccagtggtg gaagaagaag aggccctgaa tatacgattg cctgcccacg ttgtcttctc 7080 ttccatacac agtgaaaatg tagaaagatg gtttgtgagg ccaaactgtg aatgggctaa 7140 agggaggcaa agttgcactc tccttcccca gagggctcac caagagggca cacccccggg 7200 ggttctggtg ggcaacgggg gtgagcatgt ccctgccctg gctccctcca tctgtgacca 7260 ggaggcatgg ctgggtgtat gttcaggtga ggctcagagt ggcattgtgt ccctgtcccc 7320 tgcccagggc agtgagggga gcccttgatg ctgattagaa ggctagaact ggggtagagg 7380 tgcctggcat gtctcatgcc atggggactc aatctagcaa ctgtgagtcc tggggtccct 7440 gtgatgggaa gagggcagtg ccctgcccaa tgtggcaggt gtcctcatgg caggatctgc 7500 ccctcaccag ggggctggga tctacttgct tggagctctg agcaaggcca caatgcccgc 7560 ccccaccccc aagtagactg cagcctgggc ctcatggggc ttctcccagg cccacatggc 7620 atccctctct gagtttccag gccaccgtgg gaccctgcag agcatctgca ccgggctgga 7680 tagggcagaa aagctcaagg gcagctagct tgcctcttcc ctggaagaaa ggtgctctgg 7740 gactcaccaa ccctgagaaa gatagctttc ctggccacca ccattcccca ccaccctgga 7800 gaagccaatt cccaggcttg aagggcactg gctggcagga ggcctcttca ttctgcagga 7860 ggtggaaagg acacctgtag acaggtgatg ctcacccctc acctggcgcc atggggctgg 7920 gaggtgagcg gctggcatgt ttgttcctag ggagcaccat gtgagcttaa ggctcccctg 7980 accggcccca ccacatggcc cagcctccta gcacagcagc gctgacctca gtgcagtctg 8040 aggattggaa tccaccatga gatgatgtga gagctgtgtg ccccaggatc aactttttct 8100 ccaacttggc catcagccag cgagttgcta aggacctgag tcagcactca cgttgcctat 8160 tcacactccg cttgaaagtc cggaaggtgg ctactgcaaa atcacccctc tgagaagtcc 8220 tctctccaca tcttgtcccc ctttgtgaag acccctagtt cgctctgcat tttaggcatg 8280 aagagataca gcagggtgcg tccggaggga gctgtggcct tgcaacacca ctggcaacag 8340 ggccggggct cccggtgaag gtgtcaggaa gtggaaaagg ctggactttg tctcctcttt 8400 gcctgctggt agcctaaccg caaaagtatc tctttataca gaatacttac agattctaat 8460 atatatttgt atttcatttt gttacagtat ttttatatgt taaagtcaac atccagcgtc 8520 ttgttttgcc tttcagatgc tatgtggtcg tggcacgttt tgttgggggt ttctgtagtc 8580 gtcttgtttg gatcaactcc tagaggctgg tttagaacag gcccatgagg gagctgcacc 8640 tgccctggaa gtattgtttt agactatgtc gatattgtct gttgtcttcc atgtgaacat 8700 gacattgagt cactctg 8717 5 767 DNA Homo sapien misc_feature (762)..(762) n is a, c, g, or t 5 gcgaaacggc agaggagccg agccccctcc gcccaaggcg ccctccctcc gtccgcgcac 60 aggcgccgtc gcttggagga ccaaggtgcc tcccagcccg caggggcgcc gcgcgcaagc 120 ccgcgggctc ttcggtggct ctgccccggg actgcacctg gaggcggccc cggacgggga 180 tggtcagcgg ctgctgccgt ctggctcgcg agcgggacgc tgtgagggca ccatggcgct 240 gactcccggg tgggggtcct cggcggggcc ggtccggccg gagctctggc tgctgctgtg 300 ggcagccgcg tggcgcctgg gtgcctcggc gtgccccgcc ctctgcacct gcaccggaac 360 cacggtggac tgccacggca cggggctgca ggccattccc aagaatatac ctcggaacac 420 cgagcgcctg gaactcaatg gcaacaacat cactcggatc cataagaatg actttgcggg 480 gctcaagcag ctgcgggtgc tgcagctgat ggagaaccag attggagcag tggaacgtgg 540 tgcttttgat gacatgaagg agctggagcg gctgcgactg aaccgaaacc agctgcacat 600 gttaccggaa ctgctgttcc agaacaacca ggctttgtca agactgatct atggctcaga 660 gaggtgattt gccttggacc acagagcagc ttgacaatag ggttggaatt agacaccagg 720 ccttctaggg gccctgaaga gcctgaaaat ggtcttaaac cntgacc 767 6 1534 PRT Homo sapien 6 Met Ala Leu Thr Pro Gly Trp Gly Ser Ser Ala Gly Pro Val Arg Pro 1 5 10 15 Glu Leu Trp Leu Leu Leu Trp Ala Ala Ala Trp Arg Leu Gly Ala Ser 20 25 30 Ala Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His 35 40 45 Gly Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu 50 55 60 Arg Leu Glu Leu Asn Gly Asn Asn Ile Thr Arg Ile His Lys Asn Asp 65 70 75 80 Phe Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Gln 85 90 95 Ile Gly Ala Val Glu Arg Gly Ala Phe Asp Asp Met Lys Glu Leu Glu 100 105 110 Arg Leu Arg Leu Asn Arg Asn Gln Leu His Met Leu Pro Glu Leu Leu 115 120 125 Phe Gln Asn Asn Gln Ala Leu Ser Arg Leu Asp Leu Ser Glu Asn Ala 130 135 140 Ile Gln Ala Ile Pro Arg Lys Ala Phe Arg Gly Ala Thr Asp Leu Lys 145 150 155 160 Asn Leu Arg Leu Asp Lys Asn Gln Ile Ser Cys Ile Glu Glu Gly Ala 165 170 175 Phe Arg Ala Leu Arg Gly Leu Glu Val Leu Thr Leu Asn Asn Asn Asn 180 185 190 Ile Thr Thr Ile Pro Val Ser Ser Phe Asn His Met Pro Lys Leu Arg 195 200 205 Thr Phe Arg Leu His Ser Asn His Leu Phe Cys Asp Cys His Leu Ala 210 215 220 Trp Leu Ser Gln Trp Leu Arg Gln Arg Pro Thr Ile Gly Leu Phe Thr 225 230 235 240 Gln Cys Ser Gly Pro Ala Ser Leu Arg Gly Leu Asn Val Ala Glu Val 245 250 255 Gln Lys Ser Glu Phe Ser Cys Ser Gly Gln Gly Glu Ala Gly Arg Val 260 265 270 Pro Thr Cys Thr Leu Ser Ser Gly Ser Cys Pro Ala Met Cys Thr Cys 275 280 285 Ser Asn Gly Ile Val Asp Cys Arg Gly Lys Gly Leu Thr Ala Ile Pro 290 295 300 Ala Asn Leu Pro Glu Thr Met Thr Glu Ile Arg Leu Glu Leu Asn Gly 305 310 315 320 Ile Lys Ser Ile Pro Pro Gly Ala Phe Ser Pro Tyr Arg Lys Leu Arg 325 330 335 Arg Ile Asp Leu Ser Asn Asn Gln Ile Ala Glu Ile Ala Pro Asp Ala 340 345 350 Phe Gln Gly Leu Arg Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Lys 355 360 365 Ile Thr Asp Leu Pro Arg Gly Val Phe Gly Gly Leu Tyr Thr Leu Gln 370 375 380 Leu Leu Leu Leu Asn Ala Asn Lys Ile Asn Cys Ile Arg Pro Asp Ala 385 390 395 400 Phe Gln Asp Leu Gln Asn Leu Ser Leu Leu Ser Leu Tyr Asp Asn Lys 405 410 415 Ile Gln Ser Leu Ala Lys Gly Thr Phe Thr Ser Leu Arg Ala Ile Gln 420 425 430 Thr Leu His Leu Ala Gln Asn Pro Phe Ile Cys Asp Cys Asn Leu Lys 435 440 445 Trp Leu Ala Asp Phe Leu Arg Thr Asn Pro Ile Glu Thr Ser Gly Ala 450 455 460 Arg Cys Ala Ser Pro Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Ile 465 470 475 480 Lys Ser Lys Lys Phe Arg Cys Ser Ala Lys Glu Gln Tyr Phe Ile Pro 485 490 495 Gly Thr Glu Asp Tyr Gln Leu Asn Ser Glu Cys Asn Ser Asp Val Val 500 505 510 Cys Pro His Lys Cys Arg Cys Glu Ala Asn Val Val Glu Cys Ser Ser 515 520 525 Leu Lys Leu Thr Lys Ile Pro Glu Arg Ile Pro Gln Ser Thr Ala Glu 530 535 540 Leu Arg Leu Asn Asn Asn Glu Ile Ser Ile Leu Glu Ala Thr Gly Met 545 550 555 560 Phe Lys Lys Leu Thr His Leu Lys Lys Ile Asn Leu Ser Asn Asn Lys 565 570 575 Val Ser Glu Ile Glu Asp Gly Ala Phe Glu Gly Ala Ala Ser Val Ser 580 585 590 Glu Leu His Leu Thr Ala Asn Gln Leu Glu Ser Ile Arg Ser Gly Met 595 600 605 Phe Arg Gly Leu Asp Gly Leu Arg Thr Leu Met Leu Arg Asn Asn Arg 610 615 620 Ile Ser Cys Ile His Asn Asp Ser Phe Thr Gly Leu Arg Asn Val Arg 625 630 635 640 Leu Leu Ser Leu Tyr Asp Asn Gln Ile Thr Thr Val Ser Pro Gly Ala 645 650 655 Phe Asp Thr Leu Gln Ser Leu Ser Thr Leu Asn Leu Leu Ala Asn Pro 660 665 670 Phe Asn Cys Asn Cys Gln Leu Ala Trp Leu Gly Gly Trp Leu Arg Lys 675 680 685 Arg Lys Ile Val Thr Gly Asn Pro Arg Cys Gln Asn Pro Asp Phe Leu 690 695 700 Arg Gln Ile Pro Leu Gln Asp Val Ala Phe Pro Asp Phe Arg Cys Glu 705 710 715 720 Glu Gly Gln Glu Glu Gly Gly Cys Leu Pro Arg Pro Gln Cys Pro Gln 725 730 735 Glu Cys Ala Cys Leu Asp Thr Val Val Arg Cys Ser Asn Lys His Leu 740 745 750 Arg Ala Leu Pro Lys Gly Ile Pro Lys Asn Val Thr Glu Leu Tyr Leu 755 760 765 Asp Gly Asn Gln Phe Thr Leu Val Pro Gly Gln Leu Ser Thr Phe Lys 770 775 780 Tyr Leu Gln Leu Val Asp Leu Ser Asn Asn Lys Ile Ser Ser Leu Ser 785 790 795 800 Asn Ser Ser Phe Thr Asn Met Ser Gln Leu Thr Thr Leu Ile Leu Ser 805 810 815 Tyr Asn Ala Leu Gln Cys Ile Pro Pro Leu Ala Phe Gln Gly Leu Arg 820 825 830 Ser Leu Arg Leu Leu Ser Leu His Gly Asn Asp Ile Ser Thr Leu Gln 835 840 845 Glu Gly Ile Phe Ala Asp Val Thr Ser Leu Ser His Leu Ala Ile Gly 850 855 860 Ala Asn Pro Leu Tyr Cys Asp Cys His Leu Arg Trp Leu Ser Ser Trp 865 870 875 880 Val Lys Thr Gly Tyr Lys Glu Pro Gly Ile Ala Arg Cys Ala Gly Pro 885 890 895 Gln Asp Met Glu Gly Lys Leu Leu Leu Thr Thr Pro Ala Lys Lys Phe 900 905 910 Glu Cys Gln Gly Pro Pro Thr Leu Ala Val Gln Ala Lys Cys Asp Leu 915 920 925 Cys Leu Ser Ser Pro Cys Gln Asn Gln Gly Thr Cys His Asn Asp Pro 930 935 940 Leu Glu Val Tyr Arg Cys Ala Cys Pro Ser Gly Tyr Lys Gly Arg Asp 945 950 955 960 Cys Glu Val Ser Leu Asn Ser Cys Ser Ser Gly Pro Cys Glu Asn Gly 965 970 975 Gly Thr Cys His Ala Gln Glu Gly Glu Asp Ala Pro Phe Thr Cys Ser 980 985 990 Cys Pro Thr Gly Phe Glu Gly Pro Thr Cys Gly Val Asn Thr Asp Asp 995 1000 1005 Cys Val Asp His Ala Cys Ala Asn Gly Gly Val Cys Val Asp Gly 1010 1015 1020 Val Gly Asn Tyr Thr Cys Gln Cys Pro Leu Gln Tyr Glu Gly Lys 1025 1030 1035 Ala Cys Glu Gln Leu Val Asp Leu Cys Ser Pro Asp Leu Asn Pro 1040 1045 1050 Cys Gln His Glu Ala Gln Cys Val Gly Thr Pro Asp Gly Pro Arg 1055 1060 1065 Cys Glu Cys Met Pro Gly Tyr Ala Gly Asp Asn Cys Ser Glu Asn 1070 1075 1080 Gln Asp Asp Cys Arg Asp His Arg Cys Gln Asn Gly Ala Gln Cys 1085 1090 1095 Met Asp Glu Val Asn Ser Tyr Ser Cys Leu Cys Ala Glu Gly Tyr 1100 1105 1110 Ser Gly Gln Leu Cys Glu Ile Pro Pro His Leu Pro Ala Pro Lys 1115 1120 1125 Ser Pro Cys Glu Gly Thr Glu Cys Gln Asn Gly Ala Asn Cys Val 1130 1135 1140 Asp Gln Gly Asn Arg Pro Val Cys Gln Cys Leu Pro Gly Phe Gly 1145 1150 1155 Gly Pro Glu Cys Glu Lys Leu Leu Ser Val Asn Phe Val Asp Arg 1160 1165 1170 Asp Thr Tyr Leu Gln Phe Thr Asp Leu Gln Asn Trp Pro Arg Ala 1175 1180 1185 Asn Ile Thr Leu Gln Val Ser Thr Ala Glu Asp Asn Gly Ile Leu 1190 1195 1200 Leu Tyr Asn Gly Asp Asn Asp His Ile Ala Val Glu Leu Tyr Gln 1205 1210 1215 Gly His Val Arg Val Ser Tyr Asp Pro Gly Ser Tyr Pro Ser Ser 1220 1225 1230 Ala Ile Tyr Ser Ala Glu Thr Ile Asn Asp Gly Gln Phe His Thr 1235 1240 1245 Val Glu Leu Val Ala Phe Asp Gln Met Val Asn Leu Ser Ile Asp 1250 1255 1260 Gly Gly Ser Pro Met Thr Met Asp Asn Phe Gly Lys His Tyr Thr 1265 1270 1275 Leu Asn Ser Glu Ala Pro Leu Tyr Val Gly Gly Met Pro Val Asp 1280 1285 1290 Val Asn Ser Ala Ala Phe Arg Leu Trp Gln Ile Leu Asn Gly Thr 1295 1300 1305 Gly Phe His Gly Cys Ile Arg Asn Leu Tyr Ile Asn Asn Glu Leu 1310 1315 1320 Gln Asp Phe Thr Lys Thr Gln Met Lys Pro Gly Val Val Pro Gly 1325 1330 1335 Cys Glu Pro Cys Arg Lys Leu Tyr Cys Leu His Gly Ile Cys Gln 1340 1345 1350 Pro Asn Ala Thr Pro Gly Pro Met Cys His Cys Glu Ala Gly Trp 1355 1360 1365 Val Gly Leu His Cys Asp Gln Pro Ala Asp Gly Pro Cys His Gly 1370 1375 1380 His Lys Cys Val His Gly Gln Cys Val Pro Leu Asp Ala Leu Ser 1385 1390 1395 Tyr Ser Cys Gln Cys Gln Asp Gly Tyr Ser Gly Ala Leu Cys Asn 1400 1405 1410 Gln Ala Gly Ala Leu Ala Glu Pro Cys Arg Gly Leu Gln Cys Leu 1415 1420 1425 His Gly His Cys Gln Ala Ser Gly Thr Lys Gly Ala His Cys Val 1430 1435 1440 Cys Asp Pro Gly Phe Ser Gly Glu Leu Cys Glu Gln Glu Ser Glu 1445 1450 1455 Cys Arg Gly Asp Pro Val Arg Asp Phe His Gln Val Gln Arg Gly 1460 1465 1470 Tyr Ala Ile Cys Gln Thr Thr Arg Pro Leu Ser Trp Val Glu Cys 1475 1480 1485 Arg Gly Ser Cys Pro Gly Gln Gly Cys Cys Gln Gly Leu Arg Leu 1490 1495 1500 Lys Arg Arg Lys Phe Thr Phe Glu Cys Ser Asp Gly Thr Ser Phe 1505 1510 1515 Ala Glu Glu Val Glu Lys Pro Thr Lys Cys Gly Cys Ala Leu Cys 1520 1525 1530 Ala 7 1461 PRT Homo sapien 7 Met Ala Leu Thr Pro Gly Trp Gly Ser Ser Ala Gly Pro Val Arg Pro 1 5 10 15 Glu Leu Trp Leu Leu Leu Trp Ala Ala Ala Trp Arg Leu Gly Ala Ser 20 25 30 Ala Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His 35 40 45 Gly Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu 50 55 60 Arg Leu Glu Leu Asn Gly Asn Asn Ile Thr Arg Ile His Lys Asn Asp 65 70 75 80 Phe Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Gln 85 90 95 Ile Gly Ala Val Glu Arg Gly Ala Phe Asp Asp Met Lys Glu Leu Glu 100 105 110 Arg Leu Arg Leu Asn Arg Asn Gln Leu His Met Leu Pro Glu Leu Leu 115 120 125 Phe Gln Asn Asn Gln Ala Leu Ser Arg Leu Asp Leu Ser Glu Asn Ala 130 135 140 Ile Gln Ala Ile Pro Arg Lys Ala Phe Arg Gly Ala Thr Asp Leu Lys 145 150 155 160 Asn Leu Arg Leu Asp Lys Asn Gln Ile Ser Cys Ile Glu Glu Gly Ala 165 170 175 Phe Arg Ala Leu Arg Gly Leu Glu Val Leu Thr Leu Asn Asn Asn Asn 180 185 190 Ile Thr Thr Ile Pro Val Ser Ser Phe Asn His Met Pro Lys Leu Arg 195 200 205 Thr Phe Arg Leu His Ser Asn His Leu Phe Cys Asp Cys His Leu Ala 210 215 220 Trp Leu Ser Gln Trp Leu Arg Gln Arg Pro Thr Ile Gly Leu Phe Thr 225 230 235 240 Gln Cys Ser Gly Pro Ala Ser Leu Arg Gly Leu Asn Val Ala Glu Val 245 250 255 Gln Lys Ser Glu Phe Ser Cys Ser Gly Gln Gly Glu Ala Gly Arg Val 260 265 270 Pro Thr Cys Thr Leu Ser Ser Gly Ser Cys Pro Ala Met Cys Thr Cys 275 280 285 Ser Asn Gly Ile Val Asp Cys Arg Gly Lys Gly Leu Thr Ala Ile Pro 290 295 300 Ala Asn Leu Pro Glu Thr Met Thr Glu Ile Arg Leu Glu Leu Asn Gly 305 310 315 320 Ile Lys Ser Ile Pro Pro Gly Ala Phe Ser Pro Tyr Arg Lys Leu Arg 325 330 335 Arg Ile Asp Leu Ser Asn Asn Gln Ile Ala Glu Ile Ala Pro Asp Ala 340 345 350 Phe Gln Gly Leu Arg Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Lys 355 360 365 Ile Thr Asp Leu Pro Arg Gly Val Phe Gly Gly Leu Tyr Thr Leu Gln 370 375 380 Leu Leu Leu Leu Asn Ala Asn Lys Ile Asn Cys Ile Arg Pro Asp Ala 385 390 395 400 Phe Gln Asp Leu Gln Asn Leu Ser Leu Leu Ser Leu Tyr Asp Asn Lys 405 410 415 Ile Gln Ser Leu Ala Lys Gly Thr Phe Thr Ser Leu Arg Ala Ile Gln 420 425 430 Thr Leu His Leu Ala Gln Asn Pro Phe Ile Cys Asp Cys Asn Leu Lys 435 440 445 Trp Leu Ala Asp Phe Leu Arg Thr Asn Pro Ile Glu Thr Ser Gly Ala 450 455 460 Arg Cys Ala Ser Pro Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Ile 465 470 475 480 Lys Ser Lys Lys Phe Arg Cys Ser Ala Lys Glu Gln Tyr Phe Ile Pro 485 490 495 Gly Thr Glu Asp Tyr Gln Leu Asn Ser Glu Cys Asn Ser Asp Val Val 500 505 510 Cys Pro His Lys Cys Arg Cys Glu Ala Asn Val Val Glu Cys Ser Ser 515 520 525 Leu Lys Leu Thr Lys Ile Pro Glu Arg Ile Pro Gln Ser Thr Ala Glu 530 535 540 Leu Arg Leu Asn Asn Asn Glu Ile Ser Ile Leu Glu Ala Thr Gly Met 545 550 555 560 Phe Lys Lys Leu Thr His Leu Lys Lys Ile Asn Leu Ser Asn Asn Lys 565 570 575 Val Ser Glu Ile Glu Asp Gly Ala Phe Glu Gly Ala Ala Ser Val Ser 580 585 590 Glu Leu His Leu Thr Ala Asn Gln Leu Glu Ser Ile Arg Ser Gly Met 595 600 605 Phe Arg Gly Leu Asp Gly Leu Arg Thr Leu Met Leu Arg Asn Asn Arg 610 615 620 Ile Ser Cys Ile His Asn Asp Ser Phe Thr Gly Leu Arg Asn Val Arg 625 630 635 640 Leu Leu Ser Leu Tyr Asp Asn Gln Ile Thr Thr Val Ser Pro Gly Ala 645 650 655 Phe Asp Thr Leu Gln Ser Leu Ser Thr Leu Asn Leu Leu Ala Asn Pro 660 665 670 Phe Asn Cys Asn Cys Gln Leu Ala Trp Leu Gly Gly Trp Leu Arg Lys 675 680 685 Arg Lys Ile Val Thr Gly Asn Pro Arg Cys Gln Asn Pro Asp Phe Leu 690 695 700 Arg Gln Ile Pro Leu Gln Asp Val Ala Phe Pro Asp Phe Arg Cys Glu 705 710 715 720 Glu Gly Gln Glu Glu Gly Gly Cys Leu Pro Arg Pro Gln Cys Pro Gln 725 730 735 Glu Cys Ala Cys Leu Asp Thr Val Val Arg Cys Ser Asn Lys His Leu 740 745 750 Arg Ala Leu Pro Lys Gly Ile Pro Lys Asn Val Thr Glu Leu Tyr Leu 755 760 765 Asp Gly Asn Gln Phe Thr Leu Val Pro Gly Gln Leu Ser Thr Phe Lys 770 775 780 Tyr Leu Gln Leu Val Asp Leu Ser Asn Asn Lys Ile Ser Ser Leu Ser 785 790 795 800 Asn Ser Ser Phe Thr Asn Met Ser Gln Leu Thr Thr Leu Ile Leu Ser 805 810 815 Tyr Asn Ala Leu Gln Cys Ile Pro Pro Leu Ala Phe Gln Gly Leu Arg 820 825 830 Ser Leu Arg Leu Leu Ser Leu His Gly Asn Asp Ile Ser Thr Leu Gln 835 840 845 Glu Gly Ile Phe Ala Asp Val Thr Ser Leu Ser His Leu Ala Ile Gly 850 855 860 Ala Asn Pro Leu Tyr Cys Asp Cys His Leu Arg Trp Leu Ser Ser Trp 865 870 875 880 Val Lys Thr Gly Tyr Lys Glu Pro Gly Ile Ala Arg Cys Ala Gly Pro 885 890 895 Gln Asp Met Glu Gly Lys Leu Leu Leu Thr Thr Pro Ala Lys Lys Phe 900 905 910 Glu Cys Gln Gly Pro Pro Thr Leu Ala Val Gln Ala Lys Cys Asp Leu 915 920 925 Cys Leu Ser Ser Pro Cys Gln Asn Gln Gly Thr Cys His Asn Asp Pro 930 935 940 Leu Glu Val Tyr Arg Cys Ala Cys Pro Ser Gly Tyr Lys Gly Arg Asp 945 950 955 960 Cys Glu Val Ser Leu Asn Ser Cys Ser Ser Gly Pro Cys Glu Asn Gly 965 970 975 Gly Thr Cys His Ala Gln Glu Gly Glu Asp Ala Pro Phe Thr Cys Ser 980 985 990 Cys Pro Thr Gly Phe Glu Gly Pro Thr Cys Gly Val Asn Thr Asp Asp 995 1000 1005 Cys Val Asp His Ala Cys Ala Asn Gly Gly Val Cys Val Asp Gly 1010 1015 1020 Val Gly Asn Tyr Thr Cys Gln Cys Pro Leu Gln Tyr Glu Gly Lys 1025 1030 1035 Ala Cys Glu Gln Leu Val Asp Leu Cys Ser Pro Asp Leu Asn Pro 1040 1045 1050 Cys Gln His Glu Ala Gln Cys Val Gly Thr Pro Asp Gly Pro Arg 1055 1060 1065 Cys Glu Cys Met Pro Gly Tyr Ala Gly Asp Asn Cys Ser Glu Asn 1070 1075 1080 Gln Asp Asp Cys Arg Asp His Arg Cys Gln Asn Gly Ala Gln Cys 1085 1090 1095 Met Asp Glu Val Asn Ser Tyr Ser Cys Leu Cys Ala Glu Gly Tyr 1100 1105 1110 Ser Gly Gln Leu Cys Glu Ile Pro Pro His Leu Pro Ala Pro Lys 1115 1120 1125 Ser Pro Cys Glu Gly Thr Glu Cys Gln Asn Gly Ala Asn Cys Val 1130 1135 1140 Asp Gln Gly Asn Arg Pro Val Cys Gln Cys Leu Pro Gly Phe Gly 1145 1150 1155 Gly Pro Glu Cys Glu Lys Leu Leu Ser Val Asn Phe Val Asp Arg 1160 1165 1170 Asp Thr Tyr Leu Gln Phe Thr Asp Leu Gln Asn Trp Pro Arg Ala 1175 1180 1185 Asn Ile Thr Leu Gln Val Ser Thr Ala Glu Asp Asn Gly Ile Leu 1190 1195 1200 Leu Tyr Asn Gly Asp Asn Asp His Ile Ala Val Glu Leu Tyr Gln 1205 1210 1215 Gly His Val Arg Val Ser Tyr Asp Pro Gly Ser Tyr Pro Ser Ser 1220 1225 1230 Ala Ile Tyr Ser Ala Glu Thr Ile Asn Asp Gly Gln Phe His Thr 1235 1240 1245 Val Glu Leu Val Ala Phe Asp Gln Met Val Asn Leu Ser Ile Asp 1250 1255 1260 Gly Gly Ser Pro Met Thr Met Asp Asn Phe Gly Lys His Tyr Thr 1265 1270 1275 Leu Asn Ser Glu Ala Pro Leu Tyr Val Gly Gly Met Pro Val Asp 1280 1285 1290 Val Asn Ser Ala Ala Phe Arg Leu Trp Gln Ile Leu Asn Gly Thr 1295 1300 1305 Gly Phe His Gly Cys Ile Arg Asn Leu Tyr Ile Asn Asn Glu Leu 1310 1315 1320 Gln Asp Phe Thr Lys Thr Gln Met Lys Pro Gly Val Val Pro Gly 1325 1330 1335 Cys Glu Pro Cys Arg Lys Leu Tyr Cys Leu His Gly Ile Cys Gln 1340 1345 1350 Pro Asn Ala Thr Pro Gly Pro Met Cys His Cys Glu Ala Gly Trp 1355 1360 1365 Val Gly Leu His Cys Asp Gln Pro Ala Asp Gly Pro Cys His Gly 1370 1375 1380 His Lys Cys Val His Gly Gln Cys Val Pro Leu Asp Ala Leu Ser 1385 1390 1395 Tyr Ser Cys Gln Cys Gln Asp Gly Tyr Ser Gly Ala Leu Cys Asn 1400 1405 1410 Gln Ala Gly Ala Leu Ala Glu Pro Cys Arg Gly Leu Gln Cys Leu 1415 1420 1425 His Gly His Cys Gln Ala Ser Gly Thr Lys Gly Ala His Cys Val 1430 1435 1440 Cys Asp Pro Gly Phe Ser Gly Glu Leu Cys Glu Gln Gly Gln Gly 1445 1450 1455 Pro Pro Ser 1460 8 144 PRT Homo sapien 8 Met Ala Leu Thr Pro Gly Trp Gly Ser Ser Ala Gly Pro Val Arg Pro 1 5 10 15 Glu Leu Trp Leu Leu Leu Trp Ala Ala Ala Trp Arg Leu Gly Ala Ser 20 25 30 Ala Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His 35 40 45 Gly Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu 50 55 60 Arg Leu Glu Leu Asn Gly Asn Asn Ile Thr Arg Ile His Lys Asn Asp 65 70 75 80 Phe Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Gln 85 90 95 Ile Gly Ala Val Glu Arg Gly Ala Phe Asp Asp Met Lys Glu Leu Glu 100 105 110 Arg Leu Arg Leu Asn Arg Asn Gln Leu His Met Leu Pro Glu Leu Leu 115 120 125 Phe Gln Asn Asn Gln Ala Leu Ser Arg Leu Ile Tyr Gly Ser Glu Arg 130 135 140 9 16 PRT Homo sapien 9 Cys Ser Asp Gly Thr Ser Phe Ala Glu Glu Val Glu Lys Pro Thr Lys 1 5 10 15 10 16 PRT Homo sapien 10 Gln Tyr Phe Ile Pro Gly Thr Glu Asp TYR Gln Leu Asn Ser Glu Cys 1 5 10 15 11 15 PRT Homo sapien 11 Gln Glu Ser Glu Cys Arg Gly Asp Pro Val Arg Asp Phe His Glu 1 5 10 15 12 14 PRT Homo sapien 12 Glu Glu Gly Gln Glu Glu Gly Gly Cys Leu Pro Arg Gln Cys 1 5 10 13 15 PRT Homo sapien 13 Asn Asn Glu Leu Gln Asp Phe Thr Lys Thr Gln Met Lys Pro Gly 1 5 10 15 14 8 PRT Homo sapien 14 Cys Glu Gln Gly Gln Pro Pro Ser 1 5 15 22 RNA Artificial Novel Sequence 15 ggggauggug gugauauugu ug 22 16 21 RNA Artificial Novel Sequence 16 agauggggag ggaucucaca g 21 17 21 RNA Artificial Novel Sequence 17 ugaacuuccu ccgcuucagc c 21 18 22 RNA Artificial Novel Sequence 18 uuucuccagc uucucccugc cc 22 19 22 RNA Artificial Novel Sequence 19 cuauugucaa gcugcucugu gg 22 20 26 RNA Artificial Novel Sequence 20 guuccugaug agucgacacg aaacug 26 21 26 RNA Artificial Novel Sequence 21 caggcugaug agucgacacg aaagau 26 22 26 RNA Artificial Novel Sequence 22 ccggcugaug agucgacacg aaacuc 26 23 26 RNA Artificial Novel Sequence 23 gauucugaug agucgacacg aaaugc 26 24 26 RNA Artificial Novel Sequence 24 ucuucugaug agucgacacg aaaggg 26 25 3386 DNA Homo sapiens 25 gagggcacca tggcgctgac tcccgggtgg gggtcctcgg cggggccggt ccggccggag 60 ctctggctgc tgctgtgggc agccgcgtgg cgcctgggtg cctcggcgtg ccccgccctc 120 tgcacctgca ccggaaccac ggtggactgc cacggcacgg ggctgcaggc cattcccaag 180 aatatacctc ggaacaccga gcgcctggaa ctcaatggca acaacatcac tcggatccat 240 aagaatgact ttgcggggct caagcagctg cgggtgctgc agctgatgga gaaccagatt 300 ggagcagtgg aacgtggtgc ttttgatgac atgaaggagc tggagcggct gcgactgaac 360 cgaaaccagc tgcacatgtt accggaactg ctgttccaga acaaccaggc tttgtcaaga 420 ctggacttga gtgagaacgc catccaggcc atccccagga aagcttttcg gggagctacg 480 gaccttaaaa atttacagct ggacaagaac cagatcagct gcattgagga aggggccttc 540 cgtgctctgc gggggctgga ggtgctgacc ctgaacaaca acaatatcac caccatcccc 600 gtgtccagct tcaaccatat gcccaagcta cggaccttcc gcctgcactc caaccacctg 660 ttttgcgact gccacctggc ctggctctcg cagtggctga ggcagcggcc aaccatcggg 720 ctcttcaccc agtgctcggg cccagccagc ctgcgtggcc tcaatgtggc agaggtccag 780 aagagtgagt tcagctgctc aggccaggga gaagcggggc gcgtgcccac ctgcaccctg 840 tcctccggct cctgcccggc catgtgcacc tgcagcaatg gcatcgtgga ctgtcgtgga 900 aaaggcctca ctgccatccc ggccaacctg cccgagacca tgacggagat acgcctggag 960 ctgaacggca tcaagtccat ccctcctgga gccttctcac cctacagaaa gctacggagg 1020 atagacctga gcaacaatca gatcgctgag attgcacccg acgccttcca gggcctccgc 1080 tccctgaact cgctggtcct ctatggaaac aagatcacag acctcccccg tggtgtgttt 1140 ggaggcctat acaccctaca gctcctgctc ctgaatgcca acaagatcaa ctgcatccgg 1200 cccgatgcct tccaggacct gcagaacctc tcactgctct ccctgtatga caacaagatc 1260 cagagcctcg ccaagggcac tttcacctcc ctgcgggcca tccagactct gcacctggcg 1320 cagaaccctt tcatttgcga ctgtaacctc aagtggctgg cagacttcct gcgcaccaat 1380 cccatcgaga cgagtggtgc ccgctgtgcc agtccccggc gcctcgccaa caagcgcatc 1440 gggcagatca agagcaagaa gttccggtgc tcagccaaag agcagtactt cattccaggc 1500 acggaggatt accagctgaa cagcgagtgc aacagcgacg tggtctgtcc ccacaagtgc 1560 cgctgtgagg ccaacgtggt ggagtgctcc agcctgaagc tcaccaagat ccctgagcgc 1620 atcccccagt ccacggcaga actgcgattg aataacaatg agatttccat cctggaggcc 1680 actgggatgt ttaaaaaact tacacatctg aagaaaatca atctgagcaa caacaaggtg 1740 tcagaaattg aagatggggc cttcgagggc gcagcctctg tgagcgagct gcacctaact 1800 gccaaccagc tggagtccat ccggagcggc atgttccggg gtctggatgg cttgaggacc 1860 ctaatgctgc ggaacaaccg catcagctgc atccacaacg acagcttcac gggcctgcgc 1920 aacgtccggc tcctctcgct ctacgacaac cagatcacca ccgtatcccc aggagccttc 1980 gacaccctcc agtccctctc cacactgaat ctcctggcca accctttcaa ctgcaactgc 2040 cagctggcct ggctaggagg ctggctacgg aagcgcaaga tcgtgacggg gaacccgcga 2100 tgccagaacc ctgacttttt gcggcagatt cccctgcagg acgtggcctt ccctgacttc 2160 aggtgtgagg aaggccagga ggaggggggc tgcctgcccc gcccacagtg cccacaggag 2220 tgcgcctgcc tggacaccgt ggtccgatgc agcaacaagc acctgcgggc cctgcccaag 2280 ggcattccca agaatgtcac agaactctat ttggacggga accagttcac gctggttccg 2340 ggacagctgt ctaccttcaa gtacctgcag ctcgtggacc tgagcaacaa caagatcagt 2400 tccttaagca attcctcctt caccaacatg agccagctga ccactctgat cctcagctac 2460 aatgccctgc agtgcatcct gcctttggcc ttccagggac tccgctccct gcgcctgctg 2520 tctctccacg gcaatgacat ctccaccctc caagagggca tctttgcaga cgtgacctcc 2580 ctgtctcacc tggccattgg tgccaacccc ctatactgtg actgccacct ccgctggctg 2640 tccagctggg tgaagactgg ctacaaggaa ccgggcattg ctcgttgtgc tgggccccag 2700 gacatggagg gcaagctgct cctcaccacg cctgccaaga agtttgaatg ccaaggtcct 2760 ccaacgctgg ctgtccaggc caagtgtgat ctctgcttgt ccagtccgtg ccagaaccag 2820 ggcacctgcc acaacgaccc ccttgaggtg tacaggtgcg cctgccccag cggctataag 2880 ggtcgagact gtgaggtgtc cctggacagc tgttccagtg gcccctgtga aaatgggggc 2940 acctgccatg cacaggaggg cgaggatgcc ccgttcacgt gctcctgtcc caccggcttt 3000 gaaggaccaa cctgtggggt gaacacagat gactgtgtgg atcatgcctg tgccaatggg 3060 ggcgtctgtg tggatggtgt gggcaactac acctgccagt gccccctgca gtatgaggga 3120 aaggcctgtg agcagctggt ggacttgtgc tctccggatc tgaacccatg tcaacacgag 3180 gcccagtgtg tgggcacccc ggatgggccc aggtgtgagt gcatgccagg ttatgcaggt 3240 gacaactgca gtgagaacca ggatgactgc agggaccacc gctgccagaa tggggcccag 3300 tgtatggatg aagtcaacag ctactcctgc ctctgtgctg agggctacag tggacagctc 3360 tgtgagatcc ctccctaatt aggtga 3386 26 2804 DNA Homo sapiens 26 gagggcacca tggcgctgac tcccgggtgg gggtcctcgg cggggccggt ccggccggag 60 ctctggctgc tgctgtgggc agccgcgtgg cgcctgggtg cctcggcgtg ccccgccctc 120 tgcacctgca ccggaaccac ggtggactgc cacggcacgg ggctgcaggc cattcccaag 180 aatatacctc ggaacaccga gcgcctggaa ctcaatggca acaacatcac tcggatccat 240 aagaatgact ttgcggggct caagcagctg cgggtgctgc agctgatgga gaaccagatt 300 ggagcagtgg aacgtggtgc ttttgatgac atgaaggagc tggagcggct gcgactgaac 360 cgaaaccagc tgcacatgtt accggaactg ctgttccaga acaaccaggc tttgtcaaga 420 ctggacttga gtgagaacgc catccaggcc atccccagga aagcttttcg gggagctacg 480 gaccttaaaa atttacagct ggacaagaac cagatcagct gcattgagga aggggccttc 540 cgtgctctgc gggggctgga ggtgctgacc ctgaacaaca acaatatcac caccatcccc 600 gtgtccagct tcaaccatat gcccaagcta cggaccttcc gcctgcactc caaccacctg 660 ttttgcgact gccacctggc ctggctctcg cagtggctga ggcagcggcc aaccatcggg 720 ctcttcaccc agtgctcggg cccagccagc ctgcgtggcc tcaatgtggc agaggtccag 780 aagagtgagt tcagctgctc aggccaggga gaagcggggc gcgtgcccac ctgcaccctg 840 tcctccggct cctgcccggc catgtgcacc tgcagcaatg gcatcgtgga ctgtcgtgga 900 aaaggcctca ctgccatccc ggccaacctg cccgagacca tgacggagat acgcctggag 960 ctgaacggca tcaagtccat ccctcctgga gccttctcac cctacagaaa gctacggagg 1020 atagacctga gcaacaatca gatcgctgag attgcacccg acgccttcca gggcctccgc 1080 tccctgaact cgctggtcct ctatggaaac aagatcacag acctcccccg tggtgtgttt 1140 ggaggcctat acaccctaca gctcctgctc ctgaatgcca acaagatcaa ctgcatccgg 1200 cccgatgcct tccaggacct gcagaacctc tcactgctct ccctgtatga caacaagatc 1260 cagagcctcg ccaagggcac tttcacctcc ctgcgggcca tccagactct gcacctggcg 1320 cagaaccctt tcatttgcga ctgtaacctc aagtggctgg cagacttcct gcgcaccaat 1380 cccatcgaga cgagtggtgc ccgctgtgcc agtccccggc gcctcgccaa caagcgcatc 1440 gggcagatca agagcaagaa gttccggtgc tcagccaaag agcagtactt cattccaggc 1500 acggaggatt accagctgaa cagcgagtgc aacagcgacg tggtctgtcc ccacaagtgc 1560 cgctgtgagg ccaacgtggt ggagtgctcc agcctgaagc tcaccaagat ccctgagcgc 1620 atcccccagt ccacggcaga actgcgattg aataacaatg agatttccat cctggaggcc 1680 actgggatgt ttaaaaaact tacacatctg aagaaaatca atctgagcaa caacaaggtg 1740 tcagaaattg aagatggggc cttcgagggc gcagcctctg tgagcgagct gcacctaact 1800 gccaaccagc tggagtccat ccggagcggc atgttccggg gtctggatgg cttgaggacc 1860 ctaatgctgc ggaacaaccg catcagctgc atccacaacg acagcttcac gggcctgcgc 1920 aacgtccggc tcctctcgct ctacgacaac cagatcacca ccgtatcccc aggagccttc 1980 gacaccctcc agtccctctc cacactgaat ctcctggcca accctttcaa ctgcaactgc 2040 cagctggcct ggctaggagg ctggctacgg aagcgcaaga tcgtgacggg gaacccgcga 2100 tgccagaacc ctgacttttt gcggcagatt cccctgcagg acgtggcctt ccctgacttc 2160 aggtgtgagg aaggccagga ggaggggggc tgcctgcccc gcccacagtg cccacaggag 2220 tgcgcctgcc tggacaccgt ggtccgatgc agcaacaagc acctgcgggc cctgcccaag 2280 ggcattccca agaatgtcac agaactctat ttggacggga accagttcac gctggttccg 2340 ggacagctgt ctaccttcaa gtacctgcag ctcgtggacc tgagcaacaa caagatcagt 2400 tccttaagca attcctcctt caccaacatg agccagctga ccactctgat cctcagctac 2460 aatgccctgc agtgcatcct gcctttggcc ttccagggac tccgctccct gcgcctgctg 2520 tctctccacg gcaatgacat ctccaccctc caagagggca tctttgcaga cgtgacctcc 2580 ctgtctcacc tggccattgg tgccaacccc ctatactgtg actgccacct ccgctggctg 2640 tccagctggg tgaagactgg ctacaaggaa ccgggcattg ctcgttgtgc tgggccccag 2700 gacatggagg gcaagctgct cctcaccacg cctgccaaga agtttgaatg ccaaggtcct 2760 ccaacgctgg ctgtccaggc caagtgtgat ctctaaatga atag 2804 27 1122 PRT Homo sapien 27 Met Ala Leu Thr Pro Gly Trp Gly Ser Ser Ala Gly Pro Val Arg Pro 1 5 10 15 Glu Leu Trp Leu Leu Leu Trp Ala Ala Ala Trp Arg Leu Gly Ala Ser 20 25 30 Ala Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His 35 40 45 Gly Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu 50 55 60 Arg Leu Glu Leu Asn Gly Asn Asn Ile Thr Arg Ile His Lys Asn Asp 65 70 75 80 Phe Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Gln 85 90 95 Ile Gly Ala Val Glu Arg Gly Ala Phe Asp Asp Met Lys Glu Leu Glu 100 105 110 Arg Leu Arg Leu Asn Arg Asn Gln Leu His Met Leu Pro Glu Leu Leu 115 120 125 Phe Gln Asn Asn Gln Ala Leu Ser Arg Leu Asp Leu Ser Glu Asn Ala 130 135 140 Ile Gln Ala Ile Pro Arg Lys Ala Phe Arg Gly Ala Thr Asp Leu Lys 145 150 155 160 Asn Leu Gln Leu Asp Lys Asn Gln Ile Ser Cys Ile Glu Glu Gly Ala 165 170 175 Phe Arg Ala Leu Arg Gly Leu Glu Val Leu Thr Leu Asn Asn Asn Asn 180 185 190 Ile Thr Thr Ile Pro Val Ser Ser Phe Asn His Met Pro Lys Leu Arg 195 200 205 Thr Phe Arg Leu His Ser Asn His Leu Phe Cys Asp Cys His Leu Ala 210 215 220 Trp Leu Ser Gln Trp Leu Arg Gln Arg Pro Thr Ile Gly Leu Phe Thr 225 230 235 240 Gln Cys Ser Gly Pro Ala Ser Leu Arg Gly Leu Asn Val Ala Glu Val 245 250 255 Gln Lys Ser Glu Phe Ser Cys Ser Gly Gln Gly Glu Ala Gly Arg Val 260 265 270 Pro Thr Cys Thr Leu Ser Ser Gly Ser Cys Pro Ala Met Cys Thr Cys 275 280 285 Ser Asn Gly Ile Val Asp Cys Arg Gly Lys Gly Leu Thr Ala Ile Pro 290 295 300 Ala Asn Leu Pro Glu Thr Met Thr Glu Ile Arg Leu Glu Leu Asn Gly 305 310 315 320 Ile Lys Ser Ile Pro Pro Gly Ala Phe Ser Pro Tyr Arg Lys Leu Arg 325 330 335 Arg Ile Asp Leu Ser Asn Asn Gln Ile Ala Glu Ile Ala Pro Asp Ala 340 345 350 Phe Gln Gly Leu Arg Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Lys 355 360 365 Ile Thr Asp Leu Pro Arg Gly Val Phe Gly Gly Leu Tyr Thr Leu Gln 370 375 380 Leu Leu Leu Leu Asn Ala Asn Lys Ile Asn Cys Ile Arg Pro Asp Ala 385 390 395 400 Phe Gln Asp Leu Gln Asn Leu Ser Leu Leu Ser Leu Tyr Asp Asn Lys 405 410 415 Ile Gln Ser Leu Ala Lys Gly Thr Phe Thr Ser Leu Arg Ala Ile Gln 420 425 430 Thr Leu His Leu Ala Gln Asn Pro Phe Ile Cys Asp Cys Asn Leu Lys 435 440 445 Trp Leu Ala Asp Phe Leu Arg Thr Asn Pro Ile Glu Thr Ser Gly Ala 450 455 460 Arg Cys Ala Ser Pro Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Ile 465 470 475 480 Lys Ser Lys Lys Phe Arg Cys Ser Ala Lys Glu Gln Tyr Phe Ile Pro 485 490 495 Gly Thr Glu Asp Tyr Gln Leu Asn Ser Glu Cys Asn Ser Asp Val Val 500 505 510 Cys Pro His Lys Cys Arg Cys Glu Ala Asn Val Val Glu Cys Ser Ser 515 520 525 Leu Lys Leu Thr Lys Ile Pro Glu Arg Ile Pro Gln Ser Thr Ala Glu 530 535 540 Leu Arg Leu Asn Asn Asn Glu Ile Ser Ile Leu Glu Ala Thr Gly Met 545 550 555 560 Phe Lys Lys Leu Thr His Leu Lys Lys Ile Asn Leu Ser Asn Asn Lys 565 570 575 Val Ser Glu Ile Glu Asp Gly Ala Phe Glu Gly Ala Ala Ser Val Ser 580 585 590 Glu Leu His Leu Thr Ala Asn Gln Leu Glu Ser Ile Arg Ser Gly Met 595 600 605 Phe Arg Gly Leu Asp Gly Leu Arg Thr Leu Met Leu Arg Asn Asn Arg 610 615 620 Ile Ser Cys Ile His Asn Asp Ser Phe Thr Gly Leu Arg Asn Val Arg 625 630 635 640 Leu Leu Ser Leu Tyr Asp Asn Gln Ile Thr Thr Val Ser Pro Gly Ala 645 650 655 Phe Asp Thr Leu Gln Ser Leu Ser Thr Leu Asn Leu Leu Ala Asn Pro 660 665 670 Phe Asn Cys Asn Cys Gln Leu Ala Trp Leu Gly Gly Trp Leu Arg Lys 675 680 685 Arg Lys Ile Val Thr Gly Asn Pro Arg Cys Gln Asn Pro Asp Phe Leu 690 695 700 Arg Gln Ile Pro Leu Gln Asp Val Ala Phe Pro Asp Phe Arg Cys Glu 705 710 715 720 Glu Gly Gln Glu Glu Gly Gly Cys Leu Pro Arg Pro Gln Cys Pro Gln 725 730 735 Glu Cys Ala Cys Leu Asp Thr Val Val Arg Cys Ser Asn Lys His Leu 740 745 750 Arg Ala Leu Pro Lys Gly Ile Pro Lys Asn Val Thr Glu Leu Tyr Leu 755 760 765 Asp Gly Asn Gln Phe Thr Leu Val Pro Gly Gln Leu Ser Thr Phe Lys 770 775 780 Tyr Leu Gln Leu Val Asp Leu Ser Asn Asn Lys Ile Ser Ser Leu Ser 785 790 795 800 Asn Ser Ser Phe Thr Asn Met Ser Gln Leu Thr Thr Leu Ile Leu Ser 805 810 815 Tyr Asn Ala Leu Gln Cys Ile Leu Pro Leu Ala Phe Gln Gly Leu Arg 820 825 830 Ser Leu Arg Leu Leu Ser Leu His Gly Asn Asp Ile Ser Thr Leu Gln 835 840 845 Glu Gly Ile Phe Ala Asp Val Thr Ser Leu Ser His Leu Ala Ile Gly 850 855 860 Ala Asn Pro Leu Tyr Cys Asp Cys His Leu Arg Trp Leu Ser Ser Trp 865 870 875 880 Val Lys Thr Gly Tyr Lys Glu Pro Gly Ile Ala Arg Cys Ala Gly Pro 885 890 895 Gln Asp Met Glu Gly Lys Leu Leu Leu Thr Thr Pro Ala Lys Lys Phe 900 905 910 Glu Cys Gln Gly Pro Pro Thr Leu Ala Val Gln Ala Lys Cys Asp Leu 915 920 925 Cys Leu Ser Ser Pro Cys Gln Asn Gln Gly Thr Cys His Asn Asp Pro 930 935 940 Leu Glu Val Tyr Arg Cys Ala Cys Pro Ser Gly Tyr Lys Gly Arg Asp 945 950 955 960 Cys Glu Val Ser Leu Asp Ser Cys Ser Ser Gly Pro Cys Glu Asn Gly 965 970 975 Gly Thr Cys His Ala Gln Glu Gly Glu Asp Ala Pro Phe Thr Cys Ser 980 985 990 Cys Pro Thr Gly Phe Glu Gly Pro Thr Cys Gly Val Asn Thr Asp Asp 995 1000 1005 Cys Val Asp His Ala Cys Ala Asn Gly Gly Val Cys Val Asp Gly 1010 1015 1020 Val Gly Asn Tyr Thr Cys Gln Cys Pro Leu Gln Tyr Glu Gly Lys 1025 1030 1035 Ala Cys Glu Gln Leu Val Asp Leu Cys Ser Pro Asp Leu Asn Pro 1040 1045 1050 Cys Gln His Glu Ala Gln Cys Val Gly Thr Pro Asp Gly Pro Arg 1055 1060 1065 Cys Glu Cys Met Pro Gly Tyr Ala Gly Asp Asn Cys Ser Glu Asn 1070 1075 1080 Gln Asp Asp Cys Arg Asp His Arg Cys Gln Asn Gly Ala Gln Cys 1085 1090 1095 Met Asp Glu Val Asn Ser Tyr Ser Cys Leu Cys Ala Glu Gly Tyr 1100 1105 1110 Ser Gly Gln Leu Cys Glu Ile Pro Pro 1115 1120 28 928 PRT Homo sapien 28 Met Ala Leu Thr Pro Gly Trp Gly Ser Ser Ala Gly Pro Val Arg Pro 1 5 10 15 Glu Leu Trp Leu Leu Leu Trp Ala Ala Ala Trp Arg Leu Gly Ala Ser 20 25 30 Ala Cys Pro Ala Leu Cys Thr Cys Thr Gly Thr Thr Val Asp Cys His 35 40 45 Gly Thr Gly Leu Gln Ala Ile Pro Lys Asn Ile Pro Arg Asn Thr Glu 50 55 60 Arg Leu Glu Leu Asn Gly Asn Asn Ile Thr Arg Ile His Lys Asn Asp 65 70 75 80 Phe Ala Gly Leu Lys Gln Leu Arg Val Leu Gln Leu Met Glu Asn Gln 85 90 95 Ile Gly Ala Val Glu Arg Gly Ala Phe Asp Asp Met Lys Glu Leu Glu 100 105 110 Arg Leu Arg Leu Asn Arg Asn Gln Leu His Met Leu Pro Glu Leu Leu 115 120 125 Phe Gln Asn Asn Gln Ala Leu Ser Arg Leu Asp Leu Ser Glu Asn Ala 130 135 140 Ile Gln Ala Ile Pro Arg Lys Ala Phe Arg Gly Ala Thr Asp Leu Lys 145 150 155 160 Asn Leu Gln Leu Asp Lys Asn Gln Ile Ser Cys Ile Glu Glu Gly Ala 165 170 175 Phe Arg Ala Leu Arg Gly Leu Glu Val Leu Thr Leu Asn Asn Asn Asn 180 185 190 Ile Thr Thr Ile Pro Val Ser Ser Phe Asn His Met Pro Lys Leu Arg 195 200 205 Thr Phe Arg Leu His Ser Asn His Leu Phe Cys Asp Cys His Leu Ala 210 215 220 Trp Leu Ser Gln Trp Leu Arg Gln Arg Pro Thr Ile Gly Leu Phe Thr 225 230 235 240 Gln Cys Ser Gly Pro Ala Ser Leu Arg Gly Leu Asn Val Ala Glu Val 245 250 255 Gln Lys Ser Glu Phe Ser Cys Ser Gly Gln Gly Glu Ala Gly Arg Val 260 265 270 Pro Thr Cys Thr Leu Ser Ser Gly Ser Cys Pro Ala Met Cys Thr Cys 275 280 285 Ser Asn Gly Ile Val Asp Cys Arg Gly Lys Gly Leu Thr Ala Ile Pro 290 295 300 Ala Asn Leu Pro Glu Thr Met Thr Glu Ile Arg Leu Glu Leu Asn Gly 305 310 315 320 Ile Lys Ser Ile Pro Pro Gly Ala Phe Ser Pro Tyr Arg Lys Leu Arg 325 330 335 Arg Ile Asp Leu Ser Asn Asn Gln Ile Ala Glu Ile Ala Pro Asp Ala 340 345 350 Phe Gln Gly Leu Arg Ser Leu Asn Ser Leu Val Leu Tyr Gly Asn Lys 355 360 365 Ile Thr Asp Leu Pro Arg Gly Val Phe Gly Gly Leu Tyr Thr Leu Gln 370 375 380 Leu Leu Leu Leu Asn Ala Asn Lys Ile Asn Cys Ile Arg Pro Asp Ala 385 390 395 400 Phe Gln Asp Leu Gln Asn Leu Ser Leu Leu Ser Leu Tyr Asp Asn Lys 405 410 415 Ile Gln Ser Leu Ala Lys Gly Thr Phe Thr Ser Leu Arg Ala Ile Gln 420 425 430 Thr Leu His Leu Ala Gln Asn Pro Phe Ile Cys Asp Cys Asn Leu Lys 435 440 445 Trp Leu Ala Asp Phe Leu Arg Thr Asn Pro Ile Glu Thr Ser Gly Ala 450 455 460 Arg Cys Ala Ser Pro Arg Arg Leu Ala Asn Lys Arg Ile Gly Gln Ile 465 470 475 480 Lys Ser Lys Lys Phe Arg Cys Ser Ala Lys Glu Gln Tyr Phe Ile Pro 485 490 495 Gly Thr Glu Asp Tyr Gln Leu Asn Ser Glu Cys Asn Ser Asp Val Val 500 505 510 Cys Pro His Lys Cys Arg Cys Glu Ala Asn Val Val Glu Cys Ser Ser 515 520 525 Leu Lys Leu Thr Lys Ile Pro Glu Arg Ile Pro Gln Ser Thr Ala Glu 530 535 540 Leu Arg Leu Asn Asn Asn Glu Ile Ser Ile Leu Glu Ala Thr Gly Met 545 550 555 560 Phe Lys Lys Leu Thr His Leu Lys Lys Ile Asn Leu Ser Asn Asn Lys 565 570 575 Val Ser Glu Ile Glu Asp Gly Ala Phe Glu Gly Ala Ala Ser Val Ser 580 585 590 Glu Leu His Leu Thr Ala Asn Gln Leu Glu Ser Ile Arg Ser Gly Met 595 600 605 Phe Arg Gly Leu Asp Gly Leu Arg Thr Leu Met Leu Arg Asn Asn Arg 610 615 620 Ile Ser Cys Ile His Asn Asp Ser Phe Thr Gly Leu Arg Asn Val Arg 625 630 635 640 Leu Leu Ser Leu Tyr Asp Asn Gln Ile Thr Thr Val Ser Pro Gly Ala 645 650 655 Phe Asp Thr Leu Gln Ser Leu Ser Thr Leu Asn Leu Leu Ala Asn Pro 660 665 670 Phe Asn Cys Asn Cys Gln Leu Ala Trp Leu Gly Gly Trp Leu Arg Lys 675 680 685 Arg Lys Ile Val Thr Gly Asn Pro Arg Cys Gln Asn Pro Asp Phe Leu 690 695 700 Arg Gln Ile Pro Leu Gln Asp Val Ala Phe Pro Asp Phe Arg Cys Glu 705 710 715 720 Glu Gly Gln Glu Glu Gly Gly Cys Leu Pro Arg Pro Gln Cys Pro Gln 725 730 735 Glu Cys Ala Cys Leu Asp Thr Val Val Arg Cys Ser Asn Lys His Leu 740 745 750 Arg Ala Leu Pro Lys Gly Ile Pro Lys Asn Val Thr Glu Leu Tyr Leu 755 760 765 Asp Gly Asn Gln Phe Thr Leu Val Pro Gly Gln Leu Ser Thr Phe Lys 770 775 780 Tyr Leu Gln Leu Val Asp Leu Ser Asn Asn Lys Ile Ser Ser Leu Ser 785 790 795 800 Asn Ser Ser Phe Thr Asn Met Ser Gln Leu Thr Thr Leu Ile Leu Ser 805 810 815 Tyr Asn Ala Leu Gln Cys Ile Leu Pro Leu Ala Phe Gln Gly Leu Arg 820 825 830 Ser Leu Arg Leu Leu Ser Leu His Gly Asn Asp Ile Ser Thr Leu Gln 835 840 845 Glu Gly Ile Phe Ala Asp Val Thr Ser Leu Ser His Leu Ala Ile Gly 850 855 860 Ala Asn Pro Leu Tyr Cys Asp Cys His Leu Arg Trp Leu Ser Ser Trp 865 870 875 880 Val Lys Thr Gly Tyr Lys Glu Pro Gly Ile Ala Arg Cys Ala Gly Pro 885 890 895 Gln Asp Met Glu Gly Lys Leu Leu Leu Thr Thr Pro Ala Lys Lys Phe 900 905 910 Glu Cys Gln Gly Pro Pro Thr Leu Ala Val Gln Ala Lys Cys Asp Leu 915 920 925 

1. A nucleic acid, in particular an isolated nucleic acid, coding for a Slit1 or MEGF4 isoform or a fragment hereof, comprising a nucleic acid sequence with a sequence according to Seq.-ID 2, 3, 4, 5, 25, or 26, or consisting hereof.
 2. A Slit1 or MEGF4 peptide or protein, in particular isolated, comprising an amino acid sequence coded by a nucleic acid according to claim 1 or consisting hereof, or according to Seq.-ID 7, 8, 9, 10, 11, 12, 13, 14, 27, or 28 or consisting hereof, the protein or peptide preferably being functional in the generation and function of neural tissues of mammals.
 3. The use of a nucleic acid coding for Slit1 or MEGF4 and/or a Slit1 or MEGF4 peptide, in particular according to claim 1 or 2, for the detection of cancer or for the detection of a risk of the disease of cancer, wherein a tissue sample is examined for transcription or over-transcription of Slit1 or MEGF4 RNA or for expression or over-expression or a Slit1 or MEGF4 protein, the cancer disease being selected preferably from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”.
 4. The use according to claim 3, wherein a detector substance binding to a nucleic acid coding for Slit1 or MEGF4 or to a Slit1 or MEGF4 protein or peptide, preferably comprising a reporter group, is used, the binding of the said nucleic acid and/or of the said protein or peptide to the detector substance being detected in a semi-quantitative or quantitative manner.
 5. The use of a Slit1 or MEGF4 DNA, RNA or of a Slit1 or MEGF4 protein or peptide, in particular according to claim 1 or 2, and/or of a cell expressing such protein or peptide for screening for substances binding thereto, in particular prospective drugs for inhibiting the said DNA or RNA or the said protein or peptide or prospective detector substance, a prospective substance or a mixture of such prospective substances being contacted with the said DNA, RNA or the said protein or peptide, binding events being determined by means of a binding assay, and a binding prospective substance being selected, if applicable after deconvolution.
 6. The use of a substance inhibiting Slit1 or MEGF4 or binding thereto, in particular identified according to claim 5, for preparing a pharmaceutical composition for the treatment of cancer and/or a metastases generation from a primary tumor, the cancer disease or the primary tumor, respectively, preferably being selected from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”.
 7. The use according to claim 6, wherein the substance is selected from the group comprising: a) antisense oligonucleotides, siRNA, and ribozymes against a nucleic acid according to claim 1, b) an organic molecule binding to a peptide or protein according to claim 2, in particular identified according to claim 5, and having a molecular weight below 5,000, preferably below 1,000, most preferably below 300, c) an aptamer against a protein or peptide according to claim 2, in particular identified according to claim 5, d) a (monoclonal) antibody, in particular human or humanized antibody against a protein or peptide according to claim 2, e) an anti-idiotypic non-human (monoclonal) antibody, generated by means of an antibody of the sub-group d), and f) the above substances derivatized with a reporter group, a cell toxin, an immuno-stimulating component and/or a radio isotope.
 8. The use according to claim 7, wherein the substance is a mimicry compound of an antibody against a MEGF4 peptide or protein, in particular according to claim
 2. 9. The use according to claim 7, wherein the substance is an aptamer, an antisense RNA according to one of the nucleic acid sequences Seq.-ID 15 to 19, or a ribozyme according to one of the nucleic acid sequences Seq.-ID 20 to
 24. 10. The use according to one of claims 6 to 9, wherein the substance in addition carries a cytotoxic and/or immunostimulating component.
 11. The use according to one of claims 6 to 10, wherein the pharmaceutical composition is provided for the local application in tissue containing tumor cells.
 12. A method for diagnosing a cancer disease, wherein a detector substance according to claims 6 to 11 in the embodiment with a reporter group is applied in vitro or in vivo into tissue to be examined or is contacted with a blood serum sample, the tissue to be examined or the blood serum sample being then subjected to a detection method step being sensitive for the reporter group, and wherein in the case of the detection of a defined minimum value of the reporter group in the tissue, the tissue of a respective patient is qualified as containing tumor cells.
 13. A method for treating a cancer disease, preferably a cancer disease, selected from the group comprising “prostate cancer, breast cancer, liver cancer, ovarian cancer, colon cancer, pancreas cancer and lung cancer”, wherein a pharmaceutical composition according to one of claims 6 to 11 is administered in a physiologically effective dose to a patient.
 14. A vector containing a nucleic acid according to claim
 1. 15. A cell, in particular selected from the group comprising “HEK293, Sf9 and High Five insect cells”, transfected with a nucleic acid according to claim 1 or a vector according to claim
 14. 